{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:04:30Z","timestamp":1793639070742,"version":"4.5.1"},"reference-count":381,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01794-7","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T20:34:28Z","timestamp":1775507668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors"],"prefix":"10.1186","volume":"19","author":[{"given":"Ava","family":"Safaroghli-azar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laychiluh B.","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimma","family":"Lenjisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"6","key":"1794_CR1","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.3390\/ijms22062935","volume":"22","author":"P \u0141ukasik","year":"2021","unstructured":"\u0141ukasik P, Za\u0142uski M, Gutowska I. Cyclin-dependent kinases (CDK) and their role in diseases development\u2013review. Int J Mol Sci. 2021;22(6):2935.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1794_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.tibs.2005.09.005","volume":"30","author":"M Malumbres","year":"2005","unstructured":"Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30(11):630\u201341.","journal-title":"Trends Biochem Sci"},{"key":"1794_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ejmech.2017.08.071","volume":"142","author":"S Kalra","year":"2017","unstructured":"Kalra S, Joshi G, Munshi A, Kumar R. Structural insights of cyclin dependent kinases: implications in design of selective inhibitors. Eur J Med Chem. 2017;142:424\u201358.","journal-title":"Eur J Med Chem"},{"key":"1794_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15:1\u201310.","journal-title":"Genome Biol"},{"issue":"6","key":"1794_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22(6):356\u201372. https:\/\/doi.org\/10.1038\/s41568-022-00456-3.","journal-title":"Nat Rev Cancer"},{"key":"1794_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0065-230x(08)60352-8","volume":"68","author":"M Hall","year":"1996","unstructured":"Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67\u2013108. https:\/\/doi.org\/10.1016\/s0065-230x(08)60352-8.","journal-title":"Adv Cancer Res"},{"key":"1794_CR7","doi-asserted-by":"publisher","unstructured":"Wang H, Ba J, Kang Y, Gong Z, Liang T, Zhang Y, et al. Recent Progress in CDK4\/6 Inhibitors and PROTACs. Molecules. 2023;28(24). https:\/\/doi.org\/10.3390\/molecules28248060.","DOI":"10.3390\/molecules28248060"},{"issue":"3","key":"1794_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ygyno.2020.09.012","volume":"159","author":"L Bantie","year":"2020","unstructured":"Bantie L, Tadesse S, Likisa J, Yu M, Noll B, Heinemann G, et al. A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer. Gynecol Oncol. 2020;159(3):827\u201338. https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.012.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1794_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2025.02.006","volume":"43","author":"CL Palmer","year":"2025","unstructured":"Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S, et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell. 2025;43(3):464\u201381. e14.","journal-title":"Cancer Cell"},{"issue":"2","key":"1794_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/15384101.2019.1706903","volume":"19","author":"G Tchakarska","year":"2020","unstructured":"Tchakarska G, Sola B. The double dealing of cyclin D1. Cell Cycle. 2020;19(2):163\u201378.","journal-title":"Cell Cycle"},{"issue":"46","key":"1794_CR11","doi-asserted-by":"publisher","first-page":"38523","DOI":"10.1074\/jbc.M112.366542","volume":"287","author":"E Hukkelhoven","year":"2012","unstructured":"Hukkelhoven E, Liu Y, Yeh N, Ciznadija D, Blain SW, Koff A. Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma. J Biol Chem. 2012;287(46):38523\u201330.","journal-title":"J Biol Chem"},{"key":"1794_CR12","doi-asserted-by":"publisher","unstructured":"Guiley KZ, Stevenson JW, Lou K, Barkovich KJ, Kumarasamy V, Wijeratne TU, et al. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science. 2019;366(6471). https:\/\/doi.org\/10.1126\/science.aaw2106.","DOI":"10.1126\/science.aaw2106"},{"issue":"30","key":"1794_CR13","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1038\/onc.2017.7","volume":"36","author":"B Colleoni","year":"2017","unstructured":"Colleoni B, Paternot S, Pita JM, Bisteau X, Coulonval K, Davis RJ, et al. JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21. Oncogene. 2017;36(30):4349\u201361.","journal-title":"Oncogene"},{"issue":"15","key":"1794_CR14","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1128\/mcb.01823-08","volume":"29","author":"L Bockstaele","year":"2009","unstructured":"Bockstaele L, Bisteau X, Paternot S, Roger PP. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation. Mol Cell Biol. 2009;29(15):4188\u2013200. https:\/\/doi.org\/10.1128\/mcb.01823-08.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"1794_CR15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.molcel.2019.03.020","volume":"74","author":"BR Topacio","year":"2019","unstructured":"Topacio BR, Zatulovskiy E, Cristea S, Xie S, Tambo CS, Rubin SM, et al. Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein\u2019s C-Terminal Helix. Mol Cell. 2019;74(4):758\u2013e704. https:\/\/doi.org\/10.1016\/j.molcel.2019.03.020.","journal-title":"Mol Cell"},{"key":"1794_CR16","doi-asserted-by":"publisher","unstructured":"Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. Elife. 2014;3. https:\/\/doi.org\/10.7554\/eLife.02872.","DOI":"10.7554\/eLife.02872"},{"issue":"5","key":"1794_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrm.2016.27","volume":"17","author":"P Hydbring","year":"2016","unstructured":"Hydbring P, Malumbres M, Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 2016;17(5):280\u201392.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"1794_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ccr.2011.10.001","volume":"20","author":"L Anders","year":"2011","unstructured":"Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, et al. A systematic screen for CDK4\/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011;20(5):620\u201334.","journal-title":"Cancer Cell"},{"issue":"7658","key":"1794_CR19","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nature22797","volume":"546","author":"H Wang","year":"2017","unstructured":"Wang H, Nicolay BN, Chick JM, Gao X, Geng Y, Ren H, et al. The metabolic function of cyclin D3\u2013CDK6 kinase in cancer cell survival. Nature. 2017;546(7658):426\u201330.","journal-title":"Nature"},{"issue":"3","key":"1794_CR20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1158\/0008-5472.CAN-08-2473","volume":"69","author":"MG Hu","year":"2009","unstructured":"Hu MG, Deshpande A, Enos M, Mao D, Hinds EA, Hu G-f, et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 2009;69(3):810\u20138.","journal-title":"Cancer Res"},{"key":"1794_CR21","doi-asserted-by":"crossref","unstructured":"Schirripa A, Sch\u00f6ppe H, Nebenfuehr S, Zojer M, Klampfl T, Kugler V, et al. Cdk6\u2019s functions are critically regulated by its unique C-terminus. iScience. 2025;28(2):111697.","DOI":"10.1016\/j.isci.2024.111697"},{"issue":"9","key":"1794_CR22","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1038\/sj.emboj.7601675","volume":"26","author":"T Fujimoto","year":"2007","unstructured":"Fujimoto T, Anderson K, Jacobsen SE, Nishikawa SI, Nerlov C. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C\/EBPalpha interaction. Embo j. 2007;26(9):2361\u201370. https:\/\/doi.org\/10.1038\/sj.emboj.7601675.","journal-title":"Embo j"},{"issue":"2","key":"1794_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ccr.2013.07.019","volume":"24","author":"T Otto","year":"2013","unstructured":"Otto T, Sicinski P. The kinase-independent, second life of CDK6 in transcription. Cancer Cell. 2013;24(2):141\u20133. https:\/\/doi.org\/10.1016\/j.ccr.2013.07.019.","journal-title":"Cancer Cell"},{"issue":"3","key":"1794_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.stem.2015.01.017","volume":"16","author":"E Laurenti","year":"2015","unstructured":"Laurenti E, Frelin C, Xie S, Ferrari R, Dunant CF, Zandi S, et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell. 2015;16(3):302\u201313.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"1794_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0092-8674(00)80940-X","volume":"92","author":"RX Luo","year":"1998","unstructured":"Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell. 1998;92(4):463\u201373.","journal-title":"Cell"},{"issue":"1","key":"1794_CR26","doi-asserted-by":"publisher","first-page":"16810","DOI":"10.1038\/s41598-022-20769-5","volume":"12","author":"S Kim","year":"2022","unstructured":"Kim S, Leong A, Kim M, Yang HW. CDK4\/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1\/S transition. Sci Rep. 2022;12(1):16810.","journal-title":"Sci Rep"},{"key":"1794_CR27","doi-asserted-by":"crossref","unstructured":"Konagaya Y, Rosenthal D, Ratnayeke N, Fan Y, Meyer T. An intermediate Rb\u2013E2F activity state safeguards proliferation commitment. Nature. 2024;631:424\u201331.","DOI":"10.1038\/s41586-024-07554-2"},{"issue":"6996","key":"1794_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature02650","volume":"430","author":"I Matsuura","year":"2004","unstructured":"Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004;430(6996):226\u201331.","journal-title":"Nature"},{"issue":"10","key":"1794_CR29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9 J. TGF\u03b2 signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616\u201330.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1794_CR30","doi-asserted-by":"publisher","unstructured":"Decker JT, Ma JA, Shea LD, Jeruss JS. Implications of TGF\u03b2 Signaling and CDK Inhibition for the Treatment of Breast Cancer. Cancers (Basel). 2021;13(21). https:\/\/doi.org\/10.3390\/cancers13215343.","DOI":"10.3390\/cancers13215343"},{"issue":"10","key":"1794_CR31","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/1541-7786.MCR-09-0537","volume":"8","author":"S Zelivianski","year":"2010","unstructured":"Zelivianski S, Cooley A, Kall R, Jeruss JS. Cyclin-dependent kinase 4\u2013mediated phosphorylation inhibits Smad3 activity in cyclin D\u2013overexpressing breast cancer Cells. Mol Cancer Res. 2010;8(10):1375\u201387.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1794_CR32","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.1038\/ncomms6906","volume":"6","author":"I The","year":"2015","unstructured":"The I, Ruijtenberg S, Bouchet BP, Cristobal A, Prinsen MB, van Mourik T, et al. Rb and FZR1\/Cdh1 determine CDK4\/6-cyclin D requirement in C. elegans and human cancer cells. Nat Commun. 2015;6(1):5906.","journal-title":"Nat Commun"},{"issue":"11","key":"1794_CR33","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/sj.onc.1209371","volume":"25","author":"KE Knudsen","year":"2006","unstructured":"Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25(11):1620\u20138. https:\/\/doi.org\/10.1038\/sj.onc.1209371.","journal-title":"Oncogene"},{"issue":"3","key":"1794_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/sj.onc.1208200","volume":"24","author":"CE Petre-Draviam","year":"2005","unstructured":"Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, et al. A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene. 2005;24(3):431\u201344. https:\/\/doi.org\/10.1038\/sj.onc.1208200.","journal-title":"Oncogene"},{"issue":"24","key":"1794_CR35","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1038\/onc.2015.407","volume":"35","author":"AS Tigan","year":"2016","unstructured":"Tigan AS, Bellutti F, Kollmann K, Tebb G, Sexl V. CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene. 2016;35(24):3083\u201391. https:\/\/doi.org\/10.1038\/onc.2015.407.","journal-title":"Oncogene"},{"issue":"9","key":"1794_CR36","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1128\/MCB.17.9.5338","volume":"17","author":"E Neuman","year":"1997","unstructured":"Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol. 1997;17(9):5338\u201347.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"1794_CR37","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1128\/MCB.21.9.3057-3070.2001","volume":"21","author":"C Wang","year":"2001","unstructured":"Wang C, Fu M, D\u2019Amico M, Albanese C, Zhou J-N, Brownlee M, et al. Inhibition of cellular proliferation through I\u03baB kinase-independent and peroxisome proliferator-activated receptor \u03b3-dependent repression of cyclin D1. Mol Cell Biol. 2001;21(9):3057\u201370.","journal-title":"Mol Cell Biol"},{"issue":"17","key":"1794_CR38","doi-asserted-by":"publisher","first-page":"16934","DOI":"10.1074\/jbc.M500403200","volume":"280","author":"M Fu","year":"2005","unstructured":"Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X, et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor \u03b3-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem. 2005;280(17):16934\u201341.","journal-title":"J Biol Chem"},{"issue":"33","key":"1794_CR39","doi-asserted-by":"publisher","first-page":"29728","DOI":"10.1074\/jbc.M503188200","volume":"280","author":"M Fu","year":"2005","unstructured":"Fu M, Wang C, Rao M, Wu X, Bouras T, Zhang X, et al. Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem. 2005;280(33):29728\u201342.","journal-title":"J Biol Chem"},{"issue":"1","key":"1794_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","volume":"125","author":"R Scheicher","year":"2015","unstructured":"Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015;125(1):90\u2013101. https:\/\/doi.org\/10.1182\/blood-2014-06-584417.","journal-title":"Blood"},{"issue":"7","key":"1794_CR41","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrm3823","volume":"15","author":"D Mu\u00f1oz-Esp\u00edn","year":"2014","unstructured":"Mu\u00f1oz-Esp\u00edn D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15(7):482\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1794_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fonc.2013.00030","volume":"3","author":"M Alvarez-Fern\u00e1ndez","year":"2013","unstructured":"Alvarez-Fern\u00e1ndez M, Medema RH. Novel functions of FoxM1: from molecular mechanisms to cancer therapy. Front Oncol. 2013;3:30.","journal-title":"Front Oncol"},{"issue":"1","key":"1794_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0014-5793(01)02915-5","volume":"507","author":"TW Leung","year":"2001","unstructured":"Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY, et al. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett. 2001;507(1):59\u201366.","journal-title":"FEBS Lett"},{"issue":"10","key":"1794_CR44","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1080\/15548627.2016.1214779","volume":"12","author":"V Bourdeau","year":"2016","unstructured":"Bourdeau V, Ferbeyre G. CDK4-CDK6 inhibitors induce autophagy-mediated degradation of DNMT1 and facilitate the senescence antitumor response. Autophagy. 2016;12(10):1965\u20136.","journal-title":"Autophagy"},{"issue":"11","key":"1794_CR45","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1158\/0008-5472.CAN-15-2347","volume":"76","author":"M Acevedo","year":"2016","unstructured":"Acevedo M, Vernier M, Mignacca L, Lessard F, Huot G, Moiseeva O, et al. A CDK4\/6-dependent epigenetic mechanism protects cancer cells from PML-induced senescence. Cancer Res. 2016;76(11):3252\u201364.","journal-title":"Cancer Res"},{"key":"1794_CR46","doi-asserted-by":"publisher","first-page":"113676","DOI":"10.1016\/j.bcp.2019.113676","volume":"170","author":"M Bonelli","year":"2019","unstructured":"Bonelli M, La Monica S, Fumarola C, Alfieri R. Multiple effects of CDK4\/6 inhibition in cancer: From cell cycle arrest to immunomodulation. Biochem Pharmacol. 2019;170:113676.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1794_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ccr.2010.08.012","volume":"18","author":"P Aggarwal","year":"2010","unstructured":"Aggarwal P, Vaites LP, Kim JK, Mellert H, Gurung B, Nakagawa H, et al. Nuclear cyclin D1\/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell. 2010;18(4):329\u201340.","journal-title":"Cancer Cell"},{"issue":"3","key":"1794_CR48","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.CD-14-0625","volume":"5","author":"Y Li","year":"2015","unstructured":"Li Y, Chitnis N, Nakagawa H, Kita Y, Natsugoe S, Yang Y, et al. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer Discov. 2015;5(3):288\u2013303.","journal-title":"Cancer Discov"},{"issue":"36","key":"1794_CR49","doi-asserted-by":"publisher","first-page":"17990","DOI":"10.1073\/pnas.1901323116","volume":"116","author":"S AbuHammad","year":"2019","unstructured":"AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, et al., et al. Regulation of PRMT5\u2013MDM4 axis is critical in the response to CDK4\/6 inhibitors in melanoma. Proc Natl Acad Sci. 2019;116(36):17990\u20138000.","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"1794_CR50","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1158\/2159-8290.CD-17-0912","volume":"8","author":"F Bellutti","year":"2018","unstructured":"Bellutti F, Tigan A-S, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, et al. CDK6 antagonizes p53-induced responses during tumorigenesis. Cancer Discov. 2018;8(7):884\u201397.","journal-title":"Cancer Discov"},{"issue":"7","key":"1794_CR51","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/emboj.2012.17","volume":"31","author":"EC Cho","year":"2012","unstructured":"Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J, et al. Arginine methylation controls growth regulation by E2F-1. EMBO J. 2012;31(7):1785\u201397.","journal-title":"EMBO J"},{"issue":"17","key":"1794_CR52","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1158\/0008-5472.CAN-11-3549","volume":"72","author":"S Jirawatnotai","year":"2012","unstructured":"Jirawatnotai S, Hu Y, Livingston DM, Sicinski P. Proteomic identification of a direct role for cyclin d1 in DNA damage repair. Cancer Res. 2012;72(17):4289\u201393.","journal-title":"Cancer Res"},{"issue":"7033","key":"1794_CR53","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nature03404","volume":"434","author":"F Esashi","year":"2005","unstructured":"Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M, et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature. 2005;434(7033):598\u2013604.","journal-title":"Nature"},{"issue":"22","key":"1794_CR54","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/onc.2015.354","volume":"35","author":"C Chalermrujinanant","year":"2016","unstructured":"Chalermrujinanant C, Michowski W, Sittithumcharee G, Esashi F, Jirawatnotai S. Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A\/B-dependent BRCA2 phosphorylation. Oncogene. 2016;35(22):2815\u201323.","journal-title":"Oncogene"},{"issue":"9","key":"1794_CR55","first-page":"1","volume":"51","author":"E-H Choi","year":"2019","unstructured":"Choi E-H, Kim KP. E2F1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors. Exp Mol Med. 2019;51(9):1\u201312.","journal-title":"Exp Mol Med"},{"issue":"15","key":"1794_CR56","doi-asserted-by":"publisher","first-page":"11030","DOI":"10.1016\/S0021-9258(19)78087-9","volume":"269","author":"S Matsuoka","year":"1994","unstructured":"Matsuoka S, Yamaguchi M, Matsukage A. D-type cyclin-binding regions of proliferating cell nuclear antigen. J Biol Chem. 1994;269(15):11030\u20136.","journal-title":"J Biol Chem"},{"issue":"4","key":"1794_CR57","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s001090050365","volume":"77","author":"H van der Kuip","year":"1999","unstructured":"van der Kuip H, Carius B, Haque SJ, Williams BR, Huber C, Fischer T. The DNA-binding subunit p140 of replication factor C is upregulated in cycling cells and associates with G1 phase cell cycle regulatory proteins. J Mol Med (Berl). 1999;77(4):386\u201392. https:\/\/doi.org\/10.1007\/s001090050365.","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"1794_CR58","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/0092-8674(92)90518-h","volume":"71","author":"Y Xiong","year":"1992","unstructured":"Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell. 1992;71(3):505\u201314. https:\/\/doi.org\/10.1016\/0092-8674(92)90518-h.","journal-title":"Cell"},{"issue":"2","key":"1794_CR59","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.devcel.2020.06.010","volume":"54","author":"HR Shin","year":"2020","unstructured":"Shin HR, Zoncu R. The lysosome at the intersection of cellular growth and destruction. Dev Cell. 2020;54(2):226\u201338.","journal-title":"Dev Cell"},{"issue":"6","key":"1794_CR60","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1083\/jcb.201607005","volume":"214","author":"C-Y Lim","year":"2016","unstructured":"Lim C-Y, Zoncu R. The lysosome as a command-and-control center for cellular metabolism. J Cell Biol. 2016;214(6):653\u201364.","journal-title":"J Cell Biol"},{"key":"1794_CR61","doi-asserted-by":"publisher","unstructured":"Nowosad A, Besson A. Lysosomes at the Crossroads of Cell Metabolism, Cell Cycle, and Stemness. Int J Mol Sci. 2022;23(4). https:\/\/doi.org\/10.3390\/ijms23042290.","DOI":"10.3390\/ijms23042290"},{"issue":"8","key":"1794_CR62","doi-asserted-by":"publisher","first-page":"e201911036","DOI":"10.1083\/jcb.201911036","volume":"219","author":"Q Yin","year":"2020","unstructured":"Yin Q, Jian Y, Xu M, Huang X, Wang N, Liu Z, et al. CDK4\/6 regulate lysosome biogenesis through TFEB\/TFE3. J Cell Biol. 2020;219(8):e201911036.","journal-title":"J Cell Biol"},{"issue":"20","key":"1794_CR63","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-19-0708","volume":"79","author":"L Mart\u00ednez-Carreres","year":"2019","unstructured":"Mart\u00ednez-Carreres L, Puyal J, Leal-Esteban LC, Orpinell M, Castillo-Armengol J, Giralt A, et al. CDK4 regulates lysosomal function and mTORC1 activation to promote cancer cell survival. Cancer Res. 2019;79(20):5245\u201359.","journal-title":"Cancer Res"},{"key":"1794_CR64","doi-asserted-by":"crossref","unstructured":"Romero-Pozuelo J, Figlia G, Kaya O, Martin-Villalba A, Teleman AA. Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1. Cell Rep. 2020;31(2)107504.","DOI":"10.1016\/j.celrep.2020.03.068"},{"issue":"4","key":"1794_CR65","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.devcel.2017.07.019","volume":"42","author":"J Romero-Pozuelo","year":"2017","unstructured":"Romero-Pozuelo J, Demetriades C, Schroeder P, Teleman AA. CycD\/Cdk4 and discontinuities in Dpp signaling activate TORC1 in the Drosophila wing disc. Dev Cell. 2017;42(4):376\u201387. e5.","journal-title":"Dev Cell"},{"issue":"2","key":"1794_CR66","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.molcel.2017.09.034","volume":"68","author":"IC Lopez-Mejia","year":"2017","unstructured":"Lopez-Mejia IC, Lagarrigue S, Giralt A, Martinez-Carreres L, Zanou N, Denechaud P-D, et al. CDK4 phosphorylates AMPK\u03b12 to inhibit its activity and repress fatty acid oxidation. Mol Cell. 2017;68(2):336\u201349. e6.","journal-title":"Mol Cell"},{"key":"1794_CR67","doi-asserted-by":"publisher","unstructured":"Marafie SK, Al-Mulla F, Abubaker J, mTOR. Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process. Int J Mol Sci. 2024;25(11). https:\/\/doi.org\/10.3390\/ijms25116141.","DOI":"10.3390\/ijms25116141"},{"issue":"4","key":"1794_CR68","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nri3625","volume":"14","author":"AD Wells","year":"2014","unstructured":"Wells AD, Morawski PA. New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation. Nat Rev Immunol. 2014;14(4):261\u201370.","journal-title":"Nat Rev Immunol"},{"key":"1794_CR69","doi-asserted-by":"crossref","unstructured":"Rowell EA, Wells AD. The role of cyclin-dependent kinases in T-cell development, proliferation, and function. Crit Reviews\u2122 Immunol. 2006;26(3):189\u2013212.","DOI":"10.1615\/CritRevImmunol.v26.i3.10"},{"issue":"7686","key":"1794_CR70","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D\u2013CDK4 kinase destabilizes PD-L1 via cullin 3\u2013SPOP to control cancer immune surveillance. Nature. 2018;553(7686):91\u20135.","journal-title":"Nature"},{"issue":"1","key":"1794_CR71","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2018.10.034","volume":"73","author":"X Jin","year":"2019","unstructured":"Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, et al. Phosphorylated RB promotes cancer immunity by inhibiting NF-\u03baB activation and PD-L1 expression. Mol Cell. 2019;73(1):22\u201335. e6.","journal-title":"Mol Cell"},{"key":"1794_CR72","doi-asserted-by":"publisher","first-page":"650977","DOI":"10.3389\/fimmu.2021.650977","volume":"12","author":"K Klein","year":"2021","unstructured":"Klein K, Witalisz-Siepracka A, Gotthardt D, Agerer B, Locker F, Grausenburger R, et al. T cell-intrinsic CDK6 is dispensable for anti-viral and anti-tumor responses in vivo. Front Immunol. 2021;12:650977.","journal-title":"Front Immunol"},{"issue":"12","key":"1794_CR73","doi-asserted-by":"publisher","first-page":"e51847","DOI":"10.1371\/journal.pone.0051847","volume":"7","author":"H Buss","year":"2012","unstructured":"Buss H, Handschick K, Jurrmann N, Pekkonen P, Beuerlein K, M\u00fcller H, et al. Cyclin-dependent kinase 6 phosphorylates NF-\u03baB P65 at serine 536 and contributes to the regulation of inflammatory gene expression. PLoS ONE. 2012;7(12):e51847.","journal-title":"PLoS ONE"},{"issue":"29","key":"1794_CR74","doi-asserted-by":"publisher","first-page":"25531","DOI":"10.1074\/jbc.M111.256206","volume":"286","author":"EJ Hennessy","year":"2011","unstructured":"Hennessy EJ, Sheedy FJ, Santamaria D, Barbacid M, O\u2019Neill LA. Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6. J Biol Chem. 2011;286(29):25531\u20139.","journal-title":"J Biol Chem"},{"issue":"7668","key":"1794_CR75","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135.","journal-title":"Nature"},{"issue":"2","key":"1794_CR76","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8(2):216\u201333.","journal-title":"Cancer Discov"},{"issue":"1","key":"1794_CR77","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/sj.onc.1202297","volume":"18","author":"J Adnane","year":"1999","unstructured":"Adnane J, Shao Z, Robbins PD. Cyclin D1 associates with the TBP-associated factor TAFII250 to regulate Sp1-mediated transcription. Oncogene. 1999;18(1):239\u201347.","journal-title":"Oncogene"},{"issue":"11","key":"1794_CR78","doi-asserted-by":"publisher","first-page":"8847","DOI":"10.1074\/jbc.M110747200","volume":"277","author":"C Ratineau","year":"2002","unstructured":"Ratineau C, Petry MW, Mutoh H, Leiter AB. Cyclin D1 represses the basic helix-loop-helix transcription factor, BETA2\/NeuroD. J Biol Chem. 2002;277(11):8847\u201353.","journal-title":"J Biol Chem"},{"issue":"3","key":"1794_CR79","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.bbrc.2010.08.094","volume":"400","author":"K Iwatani","year":"2010","unstructured":"Iwatani K, Fujimoto T, Ito T. Cyclin D1 blocks the anti-proliferative function of RUNX3 by interfering with RUNX3\u2013p300 interaction. Biochem Biophys Res Commun. 2010;400(3):426\u201331.","journal-title":"Biochem Biophys Res Commun"},{"issue":"32","key":"1794_CR80","doi-asserted-by":"publisher","first-page":"28733","DOI":"10.1074\/jbc.M203380200","volume":"277","author":"H-m Lin","year":"2002","unstructured":"Lin H-m, Zhao L, Cheng S-y. Cyclin D1 is a ligand-independent co-repressor for thyroid hormone receptors. J Biol Chem. 2002;277(32):28733\u201341.","journal-title":"J Biol Chem"},{"issue":"3","key":"1794_CR81","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bbrc.2005.07.141","volume":"335","author":"Y Jian","year":"2005","unstructured":"Jian Y, Yan J, Wang H, Chen C, Sun M, Jiang J, et al. Cyclin D3 interacts with vitamin D receptor and regulates its transcription activity. Biochem Biophys Res Commun. 2005;335(3):739\u201348.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1794_CR82","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.bbrc.2004.07.053","volume":"321","author":"W Liu","year":"2004","unstructured":"Liu W, Sun M, Jiang J, Shen X, Sun Q, Liu W, et al. Cyclin D3 interacts with human activating transcription factor 5 and potentiates its transcription activity. Biochem Biophys Res Commun. 2004;321(4):954\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"1794_CR83","doi-asserted-by":"crossref","unstructured":"Peterson LF, Boyapati A, Ranganathan V, Iwama A, Tenen DG, Tsai S, et al. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle proteincyclind3. Mol Cell Biol.2005;25(23):10205\u201319.","DOI":"10.1128\/MCB.25.23.10205-10219.2005"},{"issue":"5200","key":"1794_CR84","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1126\/science.7863328","volume":"267","author":"SX Skapek","year":"1995","unstructured":"Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science. 1995;267(5200):1022\u20134.","journal-title":"Science"},{"issue":"21","key":"1794_CR85","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.4161\/cc.5.21.3428","volume":"5","author":"Z Li","year":"2006","unstructured":"Li Z, Wang C, Prendergast G, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle. 2006;5(21):2440\u20132.","journal-title":"Cell Cycle"},{"issue":"4","key":"1794_CR86","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1091\/mbc.e04-08-0654","volume":"16","author":"F Bienvenu","year":"2005","unstructured":"Bienvenu F, Barr\u00e9 B, Giraud S, Avril S, Coqueret O. Transcriptional regulation by a DNA-associated form of cyclin D1. Mol Biol Cell. 2005;16(4):1850\u20138.","journal-title":"Mol Biol Cell"},{"issue":"15","key":"1794_CR87","doi-asserted-by":"publisher","first-page":"6557","DOI":"10.1158\/0008-5472.CAN-05-0486","volume":"65","author":"C Wang","year":"2005","unstructured":"Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, et al. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor \u03b1 activity. Cancer Res. 2005;65(15):6557\u201367.","journal-title":"Cancer Res"},{"issue":"1","key":"1794_CR88","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4161\/cc.10.1.14243","volume":"10","author":"H Meng","year":"2011","unstructured":"Meng H, Tian L, Zhou J, Li Z, Jiao X, Li WW, et al. PACSIN 2 represses cellular migration through direct association with cyclin D1 but not its alternate splice form cyclin D1b. Cell Cycle. 2011;10(1):73\u201381.","journal-title":"Cell Cycle"},{"issue":"20","key":"1794_CR89","doi-asserted-by":"publisher","first-page":"9986","DOI":"10.1158\/0008-5472.CAN-06-1596","volume":"66","author":"Z Li","year":"2006","unstructured":"Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, et al. Cyclin D1 induction of cellular migration requires p27KIP1. Cancer Res. 2006;66(20):9986\u201394.","journal-title":"Cancer Res"},{"issue":"2","key":"1794_CR90","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2013.07.012","volume":"24","author":"K Kollmann","year":"2013","unstructured":"Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013;24(2):167\u201381.","journal-title":"Cancer Cell"},{"issue":"23","key":"1794_CR91","first-page":"2890","volume":"127","author":"IZ Uras","year":"2016","unstructured":"Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, et al. Palbociclib treatment of FLT3-ITD\u2009+\u2009AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. J Am Soc Hematol. 2016;127(23):2890\u2013902.","journal-title":"J Am Soc Hematol"},{"issue":"12","key":"1794_CR92","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/ph13120418","volume":"13","author":"L Scheiblecker","year":"2020","unstructured":"Scheiblecker L, Kollmann K, Sexl V. CDK4\/6 and MAPK\u2014crosstalk as opportunity for cancer treatment. Pharmaceuticals. 2020;13(12):418.","journal-title":"Pharmaceuticals"},{"issue":"12","key":"1794_CR93","first-page":"4325","volume":"10","author":"C-W Luo","year":"2020","unstructured":"Luo C-W, Hou M-F, Huang C-W, Wu C-C, Ou-Yang F, Li Q-L, et al. The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer. Am J Cancer Res. 2020;10(12):4325.","journal-title":"Am J Cancer Res"},{"issue":"14","key":"1794_CR94","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1073\/pnas.0501203102","volume":"102","author":"JT Lim","year":"2005","unstructured":"Lim JT, Mansukhani M, Weinstein IB. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci U S A. 2005;102(14):5156\u201361. https:\/\/doi.org\/10.1073\/pnas.0501203102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 2","key":"1794_CR95","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.semcancer.2020.01.012","volume":"67","author":"S Qie","year":"2020","unstructured":"Qie S, Diehl JA. Cyclin D degradation by E3 ligases in cancer progression and treatment. Semin Cancer Biol. 2020;67(Pt 2):159\u201370. https:\/\/doi.org\/10.1016\/j.semcancer.2020.01.012.","journal-title":"Semin Cancer Biol"},{"issue":"22","key":"1794_CR96","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1101\/gad.12.22.3499","volume":"12","author":"JA Diehl","year":"1998","unstructured":"Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12(22):3499\u2013511. https:\/\/doi.org\/10.1101\/gad.12.22.3499.","journal-title":"Genes Dev"},{"issue":"45","key":"1794_CR97","doi-asserted-by":"publisher","first-page":"35091","DOI":"10.1074\/jbc.M006324200","volume":"275","author":"O Casanovas","year":"2000","unstructured":"Casanovas O, Mir\u00f3 F, Estanyol JM, Itarte E, Agell N, Bachs O. Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem. 2000;275(45):35091\u20137. https:\/\/doi.org\/10.1074\/jbc.M006324200.","journal-title":"J Biol Chem"},{"issue":"26","key":"1794_CR98","doi-asserted-by":"publisher","first-page":"27790","DOI":"10.1074\/jbc.M403042200","volume":"279","author":"Y Zou","year":"2004","unstructured":"Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E. Mirk\/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem. 2004;279(26):27790\u20138. https:\/\/doi.org\/10.1074\/jbc.M403042200.","journal-title":"J Biol Chem"},{"issue":"24","key":"1794_CR99","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1101\/gad.854900","volume":"14","author":"JR Alt","year":"2000","unstructured":"Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000;14(24):3102\u201314. https:\/\/doi.org\/10.1101\/gad.854900.","journal-title":"Genes Dev"},{"issue":"1","key":"1794_CR100","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1371\/journal.pone.0000128","volume":"1","author":"H Okabe","year":"2006","unstructured":"Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS ONE. 2006;1(1):e128. https:\/\/doi.org\/10.1371\/journal.pone.0000128.","journal-title":"PLoS ONE"},{"issue":"3","key":"1794_CR101","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molcel.2006.09.007","volume":"24","author":"DI Lin","year":"2006","unstructured":"Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell. 2006;24(3):355\u201366. https:\/\/doi.org\/10.1016\/j.molcel.2006.09.007.","journal-title":"Mol Cell"},{"issue":"8","key":"1794_CR102","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1101\/gad.11.8.957","volume":"11","author":"JA Diehl","year":"1997","unstructured":"Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997;11(8):957\u201372. https:\/\/doi.org\/10.1101\/gad.11.8.957.","journal-title":"Genes Dev"},{"issue":"7","key":"1794_CR103","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/15216540701488358","volume":"59","author":"ET C\u00e1nepa","year":"2007","unstructured":"C\u00e1nepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life. 2007;59(7):419\u201326. https:\/\/doi.org\/10.1080\/15216540701488358.","journal-title":"IUBMB Life"},{"issue":"1","key":"1794_CR104","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13008-024-00115-z","volume":"19","author":"L Csergeov\u00e1","year":"2024","unstructured":"Csergeov\u00e1 L, Krbu\u0161ek D, Jano\u0161tiak R. CIP\/KIP and INK4 families as hostages of oncogenic signaling. Cell Div. 2024;19(1):11. https:\/\/doi.org\/10.1186\/s13008-024-00115-z.","journal-title":"Cell Div"},{"issue":"3","key":"1794_CR105","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/1541-7786.Mcr-10-0506","volume":"9","author":"HH Al-Khalaf","year":"2011","unstructured":"Al-Khalaf HH, Hendrayani SF, Aboussekhra A. The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination\/degradation. Mol Cancer Res. 2011;9(3):311\u20139. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-10-0506.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"1794_CR106","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1074\/jbc.C200622200","volume":"278","author":"J Gump","year":"2003","unstructured":"Gump J, Stokoe D, McCormick F. Phosphorylation of p16INK4A correlates with Cdk4 association. J Biol Chem. 2003;278(9):6619\u201322. https:\/\/doi.org\/10.1074\/jbc.C200622200.","journal-title":"J Biol Chem"},{"issue":"3","key":"1794_CR107","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.bbrc.2010.02.035","volume":"393","author":"Y Guo","year":"2010","unstructured":"Guo Y, Yuan C, Weghorst CM, Li J. IKKbeta specifically binds to P16 and phosphorylates Ser8 of P16. Biochem Biophys Res Commun. 2010;393(3):504\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2010.02.035.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"1794_CR108","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.biocel.2012.09.015","volume":"44","author":"X Wang","year":"2012","unstructured":"Wang X, Huang Y, Zhao J, Zhang Y, Lu J, Huang B. Suppression of PRMT6-mediated arginine methylation of p16 protein potentiates its ability to arrest A549 cell proliferation. Int J Biochem Cell Biol. 2012;44(12):2333\u201341. https:\/\/doi.org\/10.1016\/j.biocel.2012.09.015.","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"1794_CR109","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/cdd.2015.112","volume":"23","author":"V Quereda","year":"2016","unstructured":"Quereda V, Porlan E, Can\u00e3mero M, Dubus P, Malumbres M. An essential role for Ink4 and Cip\/Kip cell-cycle inhibitors in preventing replicative stress. Cell Death Differ. 2016;23(3):430\u201341.","journal-title":"Cell Death Differ"},{"issue":"12","key":"1794_CR110","first-page":"2624","volume":"58","author":"J Easton","year":"1998","unstructured":"Easton J, Wei T, Lahti JM, Kidd VJ. Disruption of the cyclin D\/cyclin-dependent kinase\/INK4\/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res. 1998;58(12):2624\u201332.","journal-title":"Cancer Res"},{"issue":"24","key":"1794_CR111","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1101\/gad.851100","volume":"14","author":"PD Jeffrey","year":"2000","unstructured":"Jeffrey PD, Tong L, Pavletich NP. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev. 2000;14(24):3115\u201325. https:\/\/doi.org\/10.1101\/gad.851100.","journal-title":"Genes Dev"},{"issue":"2","key":"1794_CR112","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jmb.2014.11.011","volume":"427","author":"Y Huang","year":"2015","unstructured":"Huang Y, Yoon MK, Otieno S, Lelli M, Kriwacki RW. The activity and stability of the intrinsically disordered Cip\/Kip protein family are regulated by non-receptor tyrosine kinases. J Mol Biol. 2015;427(2):371\u201386. https:\/\/doi.org\/10.1016\/j.jmb.2014.11.011.","journal-title":"J Mol Biol"},{"issue":"7","key":"1794_CR113","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1101\/gad.11.7.847","volume":"11","author":"J LaBaer","year":"1997","unstructured":"LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997;11(7):847\u201362. https:\/\/doi.org\/10.1101\/gad.11.7.847.","journal-title":"Genes Dev"},{"issue":"2","key":"1794_CR114","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cell.2006.11.047","volume":"128","author":"M Grimmler","year":"2007","unstructured":"Grimmler M, Wang Y, Mund T, Cilensek Z, Keidel EM, Waddell MB, et al. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell. 2007;128(2):269\u201380. https:\/\/doi.org\/10.1016\/j.cell.2006.11.047.","journal-title":"Cell"},{"issue":"12","key":"1794_CR115","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1158\/1541-7786.MCR-09-0317","volume":"7","author":"IS Pateras","year":"2009","unstructured":"Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, Gorgoulis VG. p57KIP2:Kip ing the cell under control. Mol Cancer Res. 2009;7(12):1902\u201319.","journal-title":"Mol Cancer Res"},{"issue":"20","key":"1794_CR116","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1128\/mcb.02300-07","volume":"28","author":"MD Larrea","year":"2008","unstructured":"Larrea MD, Liang J, Da Silva T, Hong F, Shao SH, Han K, et al. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol Cell Biol. 2008;28(20):6462\u201372. https:\/\/doi.org\/10.1128\/mcb.02300-07.","journal-title":"Mol Cell Biol"},{"key":"1794_CR117","unstructured":"James MK, Ray A, Leznova D, Blain SW. Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Molecular and cellular biology. 2008."},{"issue":"9","key":"1794_CR118","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/sj.onc.1203403","volume":"19","author":"EG Reynaud","year":"2000","unstructured":"Reynaud EG, Guillier M, Leibovitch MP, Leibovitch SA. Dimerization of the amino terminal domain of p57Kip2 inhibits cyclin D1-cdk4 kinase activity. Oncogene. 2000;19(9):1147\u201352. https:\/\/doi.org\/10.1038\/sj.onc.1203403.","journal-title":"Oncogene"},{"issue":"13","key":"1794_CR119","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1038\/emboj.2012.122","volume":"31","author":"M Joaquin","year":"2012","unstructured":"Joaquin M, Gubern A, Gonz\u00e1lez-Nu\u00f1ez D, Josu\u00e9 Ruiz E, Ferreiro I, de Nadal E, et al. The p57 CDKi integrates stress signals into cell-cycle progression to promote cell survival upon stress. Embo j. 2012;31(13):2952\u201364. https:\/\/doi.org\/10.1038\/emboj.2012.122.","journal-title":"Embo j"},{"key":"1794_CR120","doi-asserted-by":"publisher","first-page":"695770","DOI":"10.3389\/fonc.2021.695770","volume":"11","author":"M Grard","year":"2021","unstructured":"Grard M, Chatelain C, Delaunay T, Pons-Tostivint E, Bennouna J, Fonteneau JF. Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy. Front Oncol. 2021;11:695770. https:\/\/doi.org\/10.3389\/fonc.2021.695770.","journal-title":"Front Oncol"},{"issue":"1","key":"1794_CR121","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40478-024-01889-7","volume":"12","author":"D Noack","year":"2024","unstructured":"Noack D, Wach J, Barrantes-Freer A, Nicolay NH, G\u00fcresir E, Seidel C. Homozygous CDKN2A\/B deletions in low- and high-grade glioma: a meta-analysis of individual patient data and predictive values of p16 immunohistochemistry testing. Acta Neuropathol Commun. 2024;12(1):180. https:\/\/doi.org\/10.1186\/s40478-024-01889-7.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"1794_CR122","doi-asserted-by":"publisher","first-page":"pbad030","DOI":"10.1093\/pcmedi\/pbad030","volume":"6","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Wu Y, Zhang L, Wang Y, Xu G, Deng Y, et al. Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas. Precis Clin Med. 2023;6(4):pbad030. https:\/\/doi.org\/10.1093\/pcmedi\/pbad030.","journal-title":"Precis Clin Med"},{"issue":"22","key":"1794_CR123","first-page":"5535","volume":"53","author":"ZA Khatib","year":"1993","unstructured":"Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 1993;53(22):5535\u201341.","journal-title":"Cancer Res"},{"issue":"1","key":"1794_CR124","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1038\/s41598-022-16455-1","volume":"12","author":"A Martinez-Monleon","year":"2022","unstructured":"Martinez-Monleon A, Kryh \u00d6berg H, Gaarder J, Berbegall AP, Javanmardi N, Djos A, et al. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. Sci Rep. 2022;12(1):12420.","journal-title":"Sci Rep"},{"key":"1794_CR125","unstructured":"He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day RS, 3rd, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994;54(22):5804\u20137."},{"issue":"6","key":"1794_CR126","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","volume":"32","author":"X Gong","year":"2017","unstructured":"Gong X, Litchfield LM, Webster Y, Chio LC, Wong SS, Stewart TR, et al. Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. Cancer Cell. 2017;32(6):761\u2013e766. https:\/\/doi.org\/10.1016\/j.ccell.2017.11.006.","journal-title":"Cancer Cell"},{"issue":"38","key":"1794_CR127","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1038\/sj.onc.1206868","volume":"22","author":"G Moreno-Bueno","year":"2003","unstructured":"Moreno-Bueno G, Rodr\u00edguez-Perales S, S\u00e1nchez-Est\u00e9vez C, Hardisson D, Sarri\u00f3 D, Prat J, et al. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene. 2003;22(38):6115\u20138. https:\/\/doi.org\/10.1038\/sj.onc.1206868.","journal-title":"Oncogene"},{"issue":"47","key":"1794_CR128","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1038\/sj.onc.1209644","volume":"25","author":"S Benzeno","year":"2006","unstructured":"Benzeno S, Lu F, Guo M, Barbash O, Zhang F, Herman JG, et al. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene. 2006;25(47):6291\u2013303. https:\/\/doi.org\/10.1038\/sj.onc.1209644.","journal-title":"Oncogene"},{"issue":"1","key":"1794_CR129","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ccr.2008.05.017","volume":"14","author":"O Barbash","year":"2008","unstructured":"Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H, et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell. 2008;14(1):68\u201378. https:\/\/doi.org\/10.1016\/j.ccr.2008.05.017.","journal-title":"Cancer Cell"},{"issue":"7856","key":"1794_CR130","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41586-021-03445-y","volume":"592","author":"D Simoneschi","year":"2021","unstructured":"Simoneschi D, Rona G, Zhou N, Jeong YT, Jiang S, Milletti G, et al. CRL4(AMBRA1) is a master regulator of D-type cyclins. Nature. 2021;592(7856):789\u201393. https:\/\/doi.org\/10.1038\/s41586-021-03445-y.","journal-title":"Nature"},{"issue":"1","key":"1794_CR131","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/ng0196-97","volume":"12","author":"L Zuo","year":"1996","unstructured":"Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996;12(1):97\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"1794_CR132","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2008-07-166801","volume":"113","author":"S Sulong","year":"2009","unstructured":"Sulong S, Moorman AV, Irving JA, Strefford JC, Konn ZJ, Case MC, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood. 2009;113(1):100\u20137. https:\/\/doi.org\/10.1182\/blood-2008-07-166801.","journal-title":"Blood"},{"issue":"17","key":"1794_CR133","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/sj.onc.1208618","volume":"24","author":"A Deshpande","year":"2005","unstructured":"Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene. 2005;24(17):2909\u201315. https:\/\/doi.org\/10.1038\/sj.onc.1208618.","journal-title":"Oncogene"},{"issue":"1","key":"1794_CR134","first-page":"13","volume":"124","author":"T Placke","year":"2014","unstructured":"Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood J Am Soc Hematol. 2014;124(1):13\u201323.","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"1794_CR135","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153\u201366. https:\/\/doi.org\/10.1038\/nrc2602.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1794_CR136","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0092-8674(00)81879-6","volume":"88","author":"RM Zwijsen","year":"1997","unstructured":"Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88(3):405\u201315.","journal-title":"Cell"},{"issue":"4","key":"1794_CR137","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2174\/156800909788486740","volume":"9","author":"J Ding","year":"2009","unstructured":"Ding J, Ning B, Huang Y, Zhang D, Li J, Chen C-Y, et al. PI3K\/Akt\/JNK\/c-Jun signaling pathway is a mediator for arsenite-induced cyclin D1 expression and cell growth in human bronchial epithelial cells. Curr Cancer Drug Targets. 2009;9(4):500\u20139.","journal-title":"Curr Cancer Drug Targets"},{"issue":"34","key":"1794_CR138","doi-asserted-by":"publisher","first-page":"20608","DOI":"10.1074\/jbc.271.34.20608","volume":"271","author":"JN Lavoie","year":"1996","unstructured":"Lavoie JN, L\u2019Allemain G, Brunet A, M\u00fcller R, Pouyss\u00e9gur J. Cyclin D1 expression is regulated positively by the p42\/p44MAPK and negatively by the p38\/HOGMAPK pathway. J Biol Chem. 1996;271(34):20608\u201316. https:\/\/doi.org\/10.1074\/jbc.271.34.20608.","journal-title":"J Biol Chem"},{"key":"1794_CR139","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1476-4598-6-24","volume":"6","author":"JP Alao","year":"2007","unstructured":"Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24. https:\/\/doi.org\/10.1186\/1476-4598-6-24.","journal-title":"Mol Cancer"},{"key":"1794_CR140","doi-asserted-by":"publisher","first-page":"620214","DOI":"10.3389\/fonc.2021.620214","volume":"11","author":"S Saha","year":"2021","unstructured":"Saha S, Dey S, Nath S. Steroid hormone receptors: links with cell cycle machinery and breast cancer progression. Front Oncol. 2021;11:620214.","journal-title":"Front Oncol"},{"issue":"46","key":"1794_CR141","doi-asserted-by":"publisher","first-page":"6271","DOI":"10.1038\/sj.onc.1203033","volume":"18","author":"MM Corcoran","year":"1999","unstructured":"Corcoran MM, Mould SJ, Orchard JA, Ibbotson RE, Chapman RM, Boright AP, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18(46):6271\u20137. https:\/\/doi.org\/10.1038\/sj.onc.1203033.","journal-title":"Oncogene"},{"issue":"4","key":"1794_CR142","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1182\/blood-2003-04-1220","volume":"102","author":"S Hayette","year":"2003","unstructured":"Hayette S, Tigaud I, Callet-Bauchu E, Ffrench M, Gazzo S, Wahbi K, et al. In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. Blood. 2003;102(4):1549\u201350.","journal-title":"Blood"},{"issue":"32","key":"1794_CR143","doi-asserted-by":"publisher","first-page":"51163","DOI":"10.18632\/oncotarget.9965","volume":"7","author":"S Lopez","year":"2016","unstructured":"Lopez S, Voisset E, Tisserand JC, Mosca C, Prebet T, Santamaria D, et al. An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. Oncotarget. 2016;7(32):51163.","journal-title":"Oncotarget"},{"issue":"4","key":"1794_CR144","first-page":"387","volume":"136","author":"J Schmoellerl","year":"2020","unstructured":"Schmoellerl J, Barbosa IAM, Eder T, Brandstoetter T, Schmidt L, Maurer B, et al. CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood J Am Soc Hematol. 2020;136(4):387\u2013400.","journal-title":"Blood J Am Soc Hematol"},{"issue":"6577","key":"1794_CR145","doi-asserted-by":"publisher","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","volume":"375","author":"A Fassl","year":"2022","unstructured":"Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: From basic science to cancer therapy. Science. 2022;375(6577):eabc1495. https:\/\/doi.org\/10.1126\/science.abc1495.","journal-title":"Science"},{"issue":"13","key":"1794_CR146","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1158\/0008-5472.CAN-08-4203","volume":"69","author":"K Matsuzaki","year":"2009","unstructured":"Matsuzaki K, Kitano C, Murata M, Sekimoto G, Yoshida K, Uemura Y, et al. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-\u03b2 signal in later stages of human colorectal cancer. Cancer Res. 2009;69(13):5321\u201330.","journal-title":"Cancer Res"},{"issue":"9","key":"1794_CR147","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41419-020-03004-9","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, Wang H, Li J, Zhang J, Wu J, Li Y, et al. FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction. Cell Death Dis. 2020;11(9):804.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1794_CR148","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1158\/1078-0432.Ccr-17-2074","volume":"24","author":"C Thangavel","year":"2018","unstructured":"Thangavel C, Boopathi E, Liu Y, McNair C, Haber A, Perepelyuk M, et al. Therapeutic Challenge with a CDK 4\/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res. 2018;24(6):1402\u201314. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2074.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1794_CR149","doi-asserted-by":"publisher","first-page":"e97448","DOI":"10.1371\/journal.pone.0097448","volume":"9","author":"Y Jia","year":"2014","unstructured":"Jia Y, Domenico J, Swasey C, Wang M, Gelfand EW, Lucas JJ. Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells. PLoS ONE. 2014;9(5):e97448.","journal-title":"PLoS ONE"},{"issue":"7","key":"1794_CR150","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/onc.2008.446","volume":"28","author":"MJ Schiewer","year":"2009","unstructured":"Schiewer MJ, Morey LM, Burd CJ, Liu Y, Merry DE, Ho S-M, et al. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene. 2009;28(7):1016\u201327.","journal-title":"Oncogene"},{"issue":"5","key":"1794_CR151","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.18632\/oncotarget.6579","volume":"7","author":"F Marampon","year":"2016","unstructured":"Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M, et al. Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage. Oncotarget. 2016;7(5):5383\u2013400. https:\/\/doi.org\/10.18632\/oncotarget.6579.","journal-title":"Oncotarget"},{"issue":"7350","key":"1794_CR152","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature10155","volume":"474","author":"S Jirawatnotai","year":"2011","unstructured":"Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011;474(7350):230\u20134.","journal-title":"Nature"},{"key":"1794_CR153","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/B978-0-12-800249-0.00004-4","volume":"121","author":"C Schaal","year":"2014","unstructured":"Schaal C, Pillai S, Chellappan SP. The Rb\u2013E2F transcriptional regulatory pathway in tumor angiogenesis and metastasis. Adv Cancer Res. 2014;121:147\u201382.","journal-title":"Adv Cancer Res"},{"key":"1794_CR154","doi-asserted-by":"publisher","first-page":"13923","DOI":"10.1038\/ncomms13923","volume":"8","author":"T Liu","year":"2017","unstructured":"Liu T, Yu J, Deng M, Yin Y, Zhang H, Luo K, et al. CDK4\/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nat Commun. 2017;8:13923. https:\/\/doi.org\/10.1038\/ncomms13923.","journal-title":"Nat Commun"},{"issue":"1","key":"1794_CR155","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1172\/jci64750","volume":"123","author":"MA Augello","year":"2013","unstructured":"Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, et al. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest. 2013;123(1):493\u2013508. https:\/\/doi.org\/10.1172\/jci64750.","journal-title":"J Clin Invest"},{"issue":"5","key":"1794_CR156","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1158\/0008-5472.Can-08-1108","volume":"70","author":"Z Zhong","year":"2010","unstructured":"Zhong Z, Yeow WS, Zou C, Wassell R, Wang C, Pestell RG, et al. Cyclin D1\/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res. 2010;70(5):2105\u201314. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-1108.","journal-title":"Cancer Res"},{"issue":"21","key":"1794_CR157","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.4161\/cc.5.21.3428","volume":"5","author":"Z Li","year":"2006","unstructured":"Li Z, Wang C, Prendergast GC, Pestell RG. Cyclin D1 functions in cell migration. Cell Cycle. 2006;5(21):2440\u20132. https:\/\/doi.org\/10.4161\/cc.5.21.3428.","journal-title":"Cell Cycle"},{"issue":"3","key":"1794_CR158","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11060-011-0692-4","volume":"106","author":"J Wang","year":"2012","unstructured":"Wang J, Wang Q, Cui Y, Liu ZY, Zhao W, Wang CL, et al. Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol. 2012;106(3):473\u201384. https:\/\/doi.org\/10.1007\/s11060-011-0692-4.","journal-title":"J Neurooncol"},{"issue":"3","key":"1794_CR159","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/(sici)1097-0215(19991029)83:3<387::aid-ijc15>3.0.co;2-o","volume":"83","author":"T Arato-Ohshima","year":"1999","unstructured":"Arato-Ohshima T, Sawa H. Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer. 1999;83(3):387\u201392. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19991029)83:3<387::aid-ijc15>3.0.co;2-o.","journal-title":"Int J Cancer"},{"issue":"3","key":"1794_CR160","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clinimag.2007.01.011","volume":"31","author":"SH Ma","year":"2007","unstructured":"Ma SH, Xu K, Xiao ZW, Wu M, Sun ZY, Wang ZX, et al. Peripheral lung cancer: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and cyclin D1 expression. Clin Imaging. 2007;31(3):165\u201377. https:\/\/doi.org\/10.1016\/j.clinimag.2007.01.011.","journal-title":"Clin Imaging"},{"issue":"15","key":"1794_CR161","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1158\/1078-0432.CCR-05-1213","volume":"12","author":"M Yasui","year":"2006","unstructured":"Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, et al. Antisense to cyclin D1 inhibits vascular endothelial growth factor\u2013stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res. 2006;12(15):4720\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1794_CR162","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0304-3835(94)03676-a","volume":"90","author":"C Dickson","year":"1995","unstructured":"Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett. 1995;90(1):43\u201350. https:\/\/doi.org\/10.1016\/0304-3835(94)03676-a.","journal-title":"Cancer Lett"},{"issue":"2","key":"1794_CR163","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1006\/bbrc.1993.2350","volume":"196","author":"Y Zhang","year":"1993","unstructured":"Zhang Y, Jiang W, Chen C, Lee CS, Kahn S, Santella R, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993;196(2):1010\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"1794_CR164","first-page":"3107","volume":"54","author":"N Nishida","year":"1994","unstructured":"Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994;54(12):3107\u201310.","journal-title":"Cancer Res"},{"issue":"7","key":"1794_CR165","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1440-1827.2007.02120.x","volume":"57","author":"Y Takahashi","year":"2007","unstructured":"Takahashi Y, Kawate S, Watanabe M, Fukushima Ji, Mori S, Fukusato T. Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver. Pathol Int. 2007;57(7):437\u201342.","journal-title":"Pathol Int"},{"issue":"2","key":"1794_CR166","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-3835(01)00651-6","volume":"172","author":"M Fujii","year":"2001","unstructured":"Fujii M, Ishiguro R, Yamashita T, Tashiro M. Cyclin D1 amplification correlates with early recurrence of squamous cell carcinoma of the tongue. Cancer Lett. 2001;172(2):187\u201392.","journal-title":"Cancer Lett"},{"issue":"7","key":"1794_CR167","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/archotol.1995.01890070076016","volume":"121","author":"SD Meredith","year":"1995","unstructured":"Meredith SD, Levine PA, Burns JA, Gaffey MJ, Boyd JC, Weiss LM, et al. Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg. 1995;121(7):790\u20134. https:\/\/doi.org\/10.1001\/archotol.1995.01890070076016.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"2","key":"1794_CR168","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s004320050243","volume":"125","author":"PT Reissmann","year":"1999","unstructured":"Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol. 1999;125(2):61\u201370. https:\/\/doi.org\/10.1007\/s004320050243.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"1794_CR169","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/bjc.1996.52","volume":"73","author":"DC Betticher","year":"1996","unstructured":"Betticher DC, Heighway J, Hasleton PS, Altermatt H, Ryder WDJ, Cerny T, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 1996;73(3):294\u2013300.","journal-title":"Br J Cancer"},{"issue":"2","key":"1794_CR170","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s0304-3835(01)00457-8","volume":"166","author":"TH Cheung","year":"2001","unstructured":"Cheung TH, Yu MM, Lo KW, Yim SF, Chung TK, Wong YF. Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett. 2001;166(2):199\u2013206. https:\/\/doi.org\/10.1016\/s0304-3835(01)00457-8.","journal-title":"Cancer Lett"},{"issue":"2","key":"1794_CR171","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ijc.20130","volume":"110","author":"G Moreno-Bueno","year":"2004","unstructured":"Moreno-Bueno G, Rodr\u00edguez-Perales S, S\u00e1nchez-Est\u00e9vez C, Marcos R, Hardisson D, Cigudosa JC, et al. Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. Int J Cancer. 2004;110(2):194\u2013200. https:\/\/doi.org\/10.1002\/ijc.20130.","journal-title":"Int J Cancer"},{"issue":"11","key":"1794_CR172","first-page":"3200","volume":"62","author":"ER Sauter","year":"2002","unstructured":"Sauter ER, Yeo U-C, von Stemm A, Zhu W, Litwin S, Tichansky DS, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002;62(11):3200\u20136.","journal-title":"Cancer Res"},{"issue":"3","key":"1794_CR173","first-page":"597","volume":"26","author":"J Utikal","year":"2005","unstructured":"Utikal J, Udart M, Leiter U, Peter RU, Kr\u00e4hn G. Additional Cyclin D1 gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma. Int J Oncol. 2005;26(3):597\u2013605.","journal-title":"Int J Oncol"},{"issue":"4","key":"1794_CR174","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000081097","volume":"25","author":"D Toncheva","year":"2004","unstructured":"Toncheva D, Petrova D, Tzenova V, Dimova I, Yankova R, Yordanov V, et al. Tissue microarray analysis of cyclin D1 gene amplification and gain in colorectal carcinomas. Tumour Biol. 2004;25(4):157\u201360. https:\/\/doi.org\/10.1159\/000081097.","journal-title":"Tumour Biol"},{"issue":"4","key":"1794_CR175","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/(SICI)1097-0215(19960822)69:4<247::AID-IJC1>3.0.CO;2-X","volume":"69","author":"F Courjal","year":"1996","unstructured":"Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer. 1996;69(4):247\u201353.","journal-title":"Int J Cancer"},{"key":"1794_CR176","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.humpath.2016.10.025","volume":"61","author":"A Ooi","year":"2017","unstructured":"Ooi A, Oyama T, Nakamura R, Tajiri R, Ikeda H, Fushida S, et al. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. Hum Pathol. 2017;61:58\u201367.","journal-title":"Hum Pathol"},{"issue":"9","key":"1794_CR177","first-page":"1634","volume":"57","author":"S Gansauge","year":"1997","unstructured":"Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 1997;57(9):1634\u20137.","journal-title":"Cancer Res"},{"issue":"7","key":"1794_CR178","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1158\/1535-7163.Mct-16-0071","volume":"15","author":"T Helsten","year":"2016","unstructured":"Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, et al. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016;15(7):1682\u201390. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0071.","journal-title":"Mol Cancer Ther"},{"issue":"12 Pt 1","key":"1794_CR179","first-page":"2229","volume":"3","author":"H Takeuchi","year":"1997","unstructured":"Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, et al. Altered p16\/MTS1\/CDKN2 and cyclin D1\/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res. 1997;3(12 Pt 1):2229\u201336.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1794_CR180","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3892\/ijo.13.3.455","volume":"13","author":"A Shamma","year":"1998","unstructured":"Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Inoue M, Yano M, et al. Effect of cyclin D1 and associated proteins on proliferation of esophageal squamous cell carcinoma. Int J Oncol. 1998;13(3):455\u201360. https:\/\/doi.org\/10.3892\/ijo.13.3.455.","journal-title":"Int J Oncol"},{"issue":"4","key":"1794_CR181","first-page":"220","volume":"7","author":"B Dey","year":"2015","unstructured":"Dey B, Raphael V, Khonglah Y, GiriLynrah K. Expression of Cyclin D1 and P16 in Esophageal Squamous Cell Carcinoma. Middle East J Dig Dis. 2015;7(4):220\u20135.","journal-title":"Middle East J Dig Dis"},{"issue":"2","key":"1794_CR182","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<380::AID-CNCR22>3.0.CO;2-W","volume":"79","author":"JA Akervall","year":"1997","unstructured":"Akervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer. 1997;79(2):380\u20139.","journal-title":"Cancer"},{"issue":"5","key":"1794_CR183","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/archotol.1997.01900050045005","volume":"123","author":"RJ Michalides","year":"1997","unstructured":"Michalides RJ, van Veelen NM, Kristel PM, Hart AA, Loftus BM, Hilgers FJ, et al. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Archives Otolaryngology\u2013Head Neck Surg. 1997;123(5):497\u2013502.","journal-title":"Archives Otolaryngology\u2013Head Neck Surg"},{"issue":"4","key":"1794_CR184","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/j.1525-1438.2006.00642.x","volume":"16","author":"W Wu","year":"2006","unstructured":"Wu W, Slomovitz BM, Soliman PT, Schmeler KM, Celestino J, Milam MR, et al. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. Int J Gynecol Cancer. 2006;16(4):1668\u201372. https:\/\/doi.org\/10.1111\/j.1525-1438.2006.00642.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"1794_CR185","first-page":"3614","volume":"6","author":"VA Fl\u00f8renes","year":"2000","unstructured":"Fl\u00f8renes VA, Faye RS, M\u00e6landsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res. 2000;6(9):3614\u201320.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1794_CR186","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/00006676-200110000-00009","volume":"23","author":"B Poch","year":"2001","unstructured":"Poch B, Gansauge F, Schwarz A, Seufferlein T, Schnelldorfer T, Ramadani M, et al. Epidermal growth factor induces cyclin D1 in human pancreatic carcinoma: Evidence for a cyclin D1\u2013dependent cell cycle progression. Pancreas. 2001;23(3):280\u20137.","journal-title":"Pancreas"},{"issue":"1","key":"1794_CR187","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1677\/joe.0.1790073","volume":"179","author":"S Guo","year":"2003","unstructured":"Guo S, Wu X, Shimoide A, Wong J, Moatamed F, Sawicki M. Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. J Endocrinol. 2003;179(1):73\u201380.","journal-title":"J Endocrinol"},{"issue":"5","key":"1794_CR188","first-page":"885","volume":"11","author":"GG McIntosh","year":"1995","unstructured":"McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995;11(5):885\u201391.","journal-title":"Oncogene"},{"issue":"2","key":"1794_CR189","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q","volume":"69","author":"C Gillett","year":"1996","unstructured":"Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 1996;69(2):92\u20139.","journal-title":"Int J Cancer"},{"issue":"18","key":"1794_CR190","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1200\/jco.2005.05.064","volume":"23","author":"A Arnold","year":"2005","unstructured":"Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23(18):4215\u201324. https:\/\/doi.org\/10.1200\/jco.2005.05.064.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1794_CR191","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3892\/etm.2011.194","volume":"2","author":"T Hashimoto","year":"2011","unstructured":"Hashimoto T, Yanaihara N, Okamoto A, Nikaido T, Saito M, Takakura S, et al. Cyclin D1 predicts the prognosis of advanced serous ovarian cancer. Exp Ther Med. 2011;2(2):213\u20139. https:\/\/doi.org\/10.3892\/etm.2011.194.","journal-title":"Exp Ther Med"},{"issue":"1","key":"1794_CR192","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/1097-0215(20001001)88:1<77::aid-ijc12>3.0.co;2-o","volume":"88","author":"JA McKay","year":"2000","unstructured":"McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J, et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer. 2000;88(1):77\u201381. https:\/\/doi.org\/10.1002\/1097-0215(20001001)88:1<77::aid-ijc12>3.0.co;2-o.","journal-title":"Int J Cancer"},{"issue":"5","key":"1794_CR193","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2559.2008.03161.x","volume":"53","author":"K Nosho","year":"2008","unstructured":"Nosho K, Kawasaki T, Chan AT, Ohnishi M, Suemoto Y, Kirkner GJ, et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology. 2008;53(5):588\u201398.","journal-title":"Histopathology"},{"issue":"3","key":"1794_CR194","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/sj.bjc.6602709","volume":"93","author":"A Mermelshtein","year":"2005","unstructured":"Mermelshtein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J, et al. Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer. 2005;93(3):338\u201345. https:\/\/doi.org\/10.1038\/sj.bjc.6602709.","journal-title":"Br J Cancer"},{"issue":"2","key":"1794_CR195","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<194::AID-PATH426>3.0.CO;2-P","volume":"189","author":"Y Takano","year":"1999","unstructured":"Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol. 1999;189(2):194\u2013200.","journal-title":"J Pathol"},{"issue":"12","key":"1794_CR196","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.humpath.2003.07.005","volume":"34","author":"RM Feakins","year":"2003","unstructured":"Feakins RM, Nickols CD, Bidd H, Walton S-J. Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol. 2003;34(12):1276\u201382.","journal-title":"Hum Pathol"},{"issue":"2","key":"1794_CR197","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1034\/j.1600-0676.2001.021002089.x","volume":"21","author":"M Joo","year":"2001","unstructured":"Joo M, Kang YK, Kim MR, Lee HK, Jang JJ. Cyclin D1 overexpression in hepatocellular carcinoma. Liver. 2001;21(2):89\u201395.","journal-title":"Liver"},{"issue":"1","key":"1794_CR198","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/(SICI)1097-0045(19990101)38:1<40::AID-PROS5>3.0.CO;2-I","volume":"38","author":"LM Gumbiner","year":"1999","unstructured":"Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, Mohler JL, et al. Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate. 1999;38(1):40\u20135.","journal-title":"Prostate"},{"issue":"11","key":"1794_CR199","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/S0046-8177(98)90262-3","volume":"29","author":"S Wang","year":"1998","unstructured":"Wang S, Wuu J, Savas L, Patwardhan N, Khan A. The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol. 1998;29(11):1304\u20139.","journal-title":"Hum Pathol"},{"issue":"5","key":"1794_CR200","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3892\/or.2016.4658","volume":"35","author":"L Zlamalikova","year":"2016","unstructured":"Zlamalikova L, Moulis M, Salek D, Jarkovsky J, Smarda J, Smardova J. Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas. Oncol Rep. 2016;35(5):2673\u201380. https:\/\/doi.org\/10.3892\/or.2016.4658.","journal-title":"Oncol Rep"},{"issue":"10","key":"1794_CR201","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1182\/blood.V85.10.2870.bloodjournal85102870","volume":"85","author":"A Delmer","year":"1995","unstructured":"Delmer A, Ajchenbaum-Cymbalista F, Tang R, Ramond S, Faussat A-M, Marie J-P, et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood. 1995;85(10):2870\u20136.","journal-title":"Blood"},{"key":"1794_CR202","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1746-1596-8-81","volume":"8","author":"T Igawa","year":"2013","unstructured":"Igawa T, Sato Y, Takata K, Iwaki N, Tanaka T, Asano N, et al. De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression. Diagn Pathol. 2013;8:81. https:\/\/doi.org\/10.1186\/1746-1596-8-81.","journal-title":"Diagn Pathol"},{"issue":"3","key":"1794_CR203","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/modpathol.2009.173","volume":"23","author":"RA Metcalf","year":"2010","unstructured":"Metcalf RA, Zhao S, Anderson MW, Lu ZS, Galperin I, Marinelli RJ, et al. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod Pathol. 2010;23(3):420\u201333. https:\/\/doi.org\/10.1038\/modpathol.2009.173.","journal-title":"Mod Pathol"},{"key":"1794_CR204","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00428-010-0969-6","volume":"457","author":"A Lopez-Beltran","year":"2010","unstructured":"Lopez-Beltran A, Ord\u00f3\u00f1ez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, et al. Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch. 2010;457:555\u201361.","journal-title":"Virchows Arch"},{"issue":"1","key":"1794_CR205","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1078-0432.242.11.1","volume":"11","author":"G Pruneri","year":"2005","unstructured":"Pruneri G, Pignataro L, Valentini S, Fabris S, Maisonneuve P, Carboni N, et al. Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. Clin Cancer Res. 2005;11(1):242\u20138.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1794_CR206","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1309\/8KF0-0Y0C-2F4L-UHXL","volume":"115","author":"MB M\u00f8ller","year":"2001","unstructured":"M\u00f8ller MB, Nielsen O, Pedersen NT. Cyclin D3 expression in non-Hodgkin lymphoma: correlation with other cell cycle regulators and clinical features. Am J Clin Pathol. 2001;115(3):404\u201312.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"1794_CR207","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/028418602753669562","volume":"41","author":"Y Hedberg","year":"2002","unstructured":"Hedberg Y, Roos G, Ljungberg B, Landberg G. Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters. Acta Oncol. 2002;41(2):175\u201381.","journal-title":"Acta Oncol"},{"issue":"10","key":"1794_CR208","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1097\/01.pas.0000170343.09562.39","volume":"29","author":"MBN Binh","year":"2005","unstructured":"Binh MBN, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagac\u00e9 R, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29(10):1340\u20137.","journal-title":"Am J Surg Pathol"},{"issue":"22","key":"1794_CR209","doi-asserted-by":"publisher","first-page":"6946","DOI":"10.1158\/1078-0432.CCR-17-0070","volume":"23","author":"Y Kong","year":"2017","unstructured":"Kong Y, Sheng X, Wu X, Yan J, Ma M, Yu J, et al. Frequent genetic aberrations in the CDK4 pathway in acral melanoma indicate the potential for CDK4\/6 inhibitors in targeted therapy. Clin Cancer Res. 2017;23(22):6946\u201357.","journal-title":"Clin Cancer Res"},{"key":"1794_CR210","doi-asserted-by":"crossref","unstructured":"Leyuan Y, Yan L, Ruiping G, Juan D, Lingchao L, Xiaolong L, et al. CDK4 gene copy number increase and concurrent genetic changes in acral melanoma of a Chinese cohort. Pathology. 2024;57(1):34\u20139.","DOI":"10.1016\/j.pathol.2024.06.012"},{"issue":"2","key":"1794_CR211","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/gcc.20122","volume":"42","author":"H Wikman","year":"2005","unstructured":"Wikman H, Nymark P, V\u00e4yrynen A, Jarmalaite S, Kallioniemi A, Salmenkivi K, et al. CDK4 is a probable target gene in a novel amplicon at 12q13. 3\u2013q14. 1 in lung cancer. Genes. Chromosomes Cancer. 2005;42(2):193\u20139.","journal-title":"Chromosomes Cancer"},{"issue":"1","key":"1794_CR212","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0002-9440(10)65257-1","volume":"154","author":"H-X An","year":"1999","unstructured":"An H-X, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol. 1999;154(1):113\u20138.","journal-title":"Am J Pathol"},{"key":"1794_CR213","doi-asserted-by":"publisher","first-page":"616110","DOI":"10.3389\/fgene.2021.616110","volume":"12","author":"J Huang","year":"2021","unstructured":"Huang J, Wang X, Zhang X, Chen W, Luan L, Song Q, et al. CDK4 Amplification in Esophageal Squamous Cell Carcinoma Associated With Better Patient Outcome. Front Genet. 2021;12:616110. https:\/\/doi.org\/10.3389\/fgene.2021.616110.","journal-title":"Front Genet"},{"issue":"24","key":"1794_CR214","first-page":"6321","volume":"54","author":"EE Schmidt","year":"1994","unstructured":"Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16\/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 1994;54(24):6321\u20134.","journal-title":"Cancer Res"},{"issue":"2","key":"1794_CR215","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/(sici)1097-0215(19990118)80:2<199::aid-ijc7>3.0.co;2-4","volume":"80","author":"G Wei","year":"1999","unstructured":"Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer. 1999;80(2):199\u2013204. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19990118)80:2<199::aid-ijc7>3.0.co;2-4.","journal-title":"Int J Cancer"},{"key":"1794_CR216","first-page":"100698","volume":"35","author":"K Liu","year":"2023","unstructured":"Liu K, Lu H, Jiang D, Guan Y, Xu H, Sun Q, et al. Prognostic significance of CDK6 amplification in esophageal squamous cell carcinoma. Cancer Treat Res Commun. 2023;35:100698.","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"1794_CR217","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.leu.2405028","volume":"22","author":"S Nagel","year":"2008","unstructured":"Nagel S, Leich E, Quentmeier H, Meyer C, Kaufmann M, Drexler H, et al. Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia. 2008;22(2):387\u201392.","journal-title":"Leukemia"},{"key":"1794_CR218","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1245\/s10434-012-2317-3","volume":"19","author":"J-W Tsai","year":"2012","unstructured":"Tsai J-W, Li C-F, Kao Y-C, Wang J-W, Fang F-M, Wang Y-H, et al. Recurrent amplification at 7q21. 2 Targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator. Ann Surg Oncol. 2012;19:2716\u201325.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1794_CR219","first-page":"209","volume":"152","author":"M Chilosi","year":"1998","unstructured":"Chilosi M, Doglioni C, Yan Z, Lestani M, Menestrina F, Sorio C, et al. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma\/leukemia. Am J Pathol. 1998;152(1):209\u201317.","journal-title":"Am J Pathol"},{"issue":"4","key":"1794_CR220","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.22034\/apjcp.2018.19.4.1013","volume":"19","author":"A Andisheh-Tadbir","year":"2018","unstructured":"Andisheh-Tadbir A, Ashraf MJ, Jeiroodi N. Expression of CDK6 in Oral Squamous Cell Carcinomas. Asian Pac J Cancer Prev. 2018;19(4):1013\u20136. https:\/\/doi.org\/10.22034\/apjcp.2018.19.4.1013.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"34","key":"1794_CR221","doi-asserted-by":"publisher","first-page":"8853","DOI":"10.1200\/jco.2005.02.8589","volume":"23","author":"F Mendrzyk","year":"2005","unstructured":"Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol. 2005;23(34):8853\u201362. https:\/\/doi.org\/10.1200\/jco.2005.02.8589.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1794_CR222","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/sj.onc.1202359","volume":"18","author":"CT Liew","year":"1999","unstructured":"Liew CT, Li H-M, Lo K-W, Leow CK, Chan JY, Hin LY, et al. High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene. 1999;18(3):789\u201395.","journal-title":"Oncogene"},{"issue":"2","key":"1794_CR223","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood.V86.2.755.bloodjournal862755","volume":"86","author":"S Takeuchi","year":"1995","unstructured":"Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JW, et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15\/MTS2\/INK4B, p16\/MTS1\/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood. 1995;86(2):755\u201360.","journal-title":"Blood"},{"issue":"3","key":"1794_CR224","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ajh.26069","volume":"96","author":"HP Wang","year":"2021","unstructured":"Wang HP, Zhou YL, Huang X, Zhang Y, Qian JJ, Li JH, et al. CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. Am J Hematol. 2021;96(3):312\u20139. https:\/\/doi.org\/10.1002\/ajh.26069.","journal-title":"Am J Hematol"},{"issue":"6","key":"1794_CR225","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1158\/1078-0432.Ccr-10-2307","volume":"17","author":"GE Konecny","year":"2011","unstructured":"Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, et al. Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer. Clin Cancer Res. 2011;17(6):1591\u2013602. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2307.","journal-title":"Clin Cancer Res"},{"key":"1794_CR226","doi-asserted-by":"publisher","first-page":"156177","DOI":"10.1016\/j.prp.2025.156177","volume":"274","author":"X Feng","year":"2025","unstructured":"Feng X, Chang H, Xu Y, Yu C, Yao Q, Jia L, et al. CDKN2A alternations in non-small cell lung cancer: An evaluation using next-generation sequencing. Pathol Res Pract. 2025;274:156177. https:\/\/doi.org\/10.1016\/j.prp.2025.156177.","journal-title":"Pathol Res Pract"},{"key":"1794_CR227","doi-asserted-by":"publisher","unstructured":"Ming Z, Lim SY, Rizos H. Genetic Alterations in the INK4a\/ARF Locus: Effects on Melanoma Development and Progression. Biomolecules. 2020;10(10). https:\/\/doi.org\/10.3390\/biom10101447.","DOI":"10.3390\/biom10101447"},{"issue":"8","key":"1794_CR228","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/gcc.22258","volume":"54","author":"AL Norris","year":"2015","unstructured":"Norris AL, Kamiyama H, Makohon-Moore A, Pallavajjala A, Morsberger LA, Lee K, et al. Transflip mutations produce deletions in pancreatic cancer. Genes Chromosomes Cancer. 2015;54(8):472\u201381. https:\/\/doi.org\/10.1002\/gcc.22258.","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"1794_CR229","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1182\/blood.V91.5.1680","volume":"91","author":"U Klangby","year":"1998","unstructured":"Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG. p16\/INK4a and p15\/INK4b gene methylation and absence of p16\/INK4a mRNA and protein expression in Burkitt\u2019s lymphoma. Blood. 1998;91(5):1680\u20137.","journal-title":"Blood"},{"issue":"3","key":"1794_CR230","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/s0002-9440(10)64261-7","volume":"161","author":"MJ Garc\u00eda","year":"2002","unstructured":"Garc\u00eda MJ, Mart\u00ednez-Delgado B, Cebrian A, Mart\u00ednez A, Ben\u00edtez J, Rivas C. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin\u2019s and CD30-Positive non-Hodgkin\u2019s lymphomas. Am J Pathol. 2002;161(3):1007\u201313. https:\/\/doi.org\/10.1016\/s0002-9440(10)64261-7.","journal-title":"Am J Pathol"},{"issue":"7","key":"1794_CR231","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1182\/blood.V89.7.2500","volume":"89","author":"MH Ng","year":"1997","unstructured":"Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood. 1997;89(7):2500\u20136.","journal-title":"Blood"},{"issue":"1","key":"1794_CR232","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/sj.leu.2401617","volume":"14","author":"M Gonz\u00e1lez","year":"2000","unstructured":"Gonz\u00e1lez M, Mateos MV, Garc\u00eda-Sanz R, Balanzategui A, L\u00f3pez-P\u00e9rez R, Chill\u00f3n MC, et al. De novo methylation of tumor suppressor gene p16\/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia. 2000;14(1):183\u20137. https:\/\/doi.org\/10.1038\/sj.leu.2401617.","journal-title":"Leukemia"},{"issue":"15","key":"1794_CR233","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/jnci\/92.15.1260","volume":"92","author":"A Borg","year":"2000","unstructured":"Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, M\u00e5sb\u00e4ck A, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000;92(15):1260\u20136. https:\/\/doi.org\/10.1093\/jnci\/92.15.1260.","journal-title":"J Natl Cancer Inst"},{"key":"1794_CR234","doi-asserted-by":"publisher","unstructured":"Saglimbeni GS, Morris TJ, Hsia B, Tauseef A. Genomic Insights into Cutaneous Squamous Cell Carcinoma. Cancers (Basel). 2026;18(4). https:\/\/doi.org\/10.3390\/cancers18040558.","DOI":"10.3390\/cancers18040558"},{"issue":"1","key":"1794_CR235","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1038\/s41467-021-24043-6","volume":"12","author":"R Li","year":"2021","unstructured":"Li R, Yang Z, Shao F, Cheng H, Wen Y, Sun S, et al. Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. Nat Commun. 2021;12(1):3785.","journal-title":"Nat Commun"},{"issue":"1","key":"1794_CR236","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4161\/15384101.2014.967118","volume":"14","author":"ES Knudsen","year":"2015","unstructured":"Knudsen ES, McClendon AK, Franco J, Ertel A, Fortina P, Witkiewicz AK. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. Cell Cycle. 2015;14(1):109\u201322.","journal-title":"Cell Cycle"},{"issue":"17","key":"1794_CR237","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1128\/mcb.24.17.7538-7547.2004","volume":"24","author":"PL Miliani de Marval","year":"2004","unstructured":"Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG, et al. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol. 2004;24(17):7538\u201347. https:\/\/doi.org\/10.1128\/mcb.24.17.7538-7547.2004.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"1794_CR238","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2005.12.012","volume":"9","author":"Q Yu","year":"2006","unstructured":"Yu Q, Sicinska E, Geng Y, Ahnstr\u00f6m M, Zagozdzon A, Kong Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell. 2006;9(1):23\u201332. https:\/\/doi.org\/10.1016\/j.ccr.2005.12.012.","journal-title":"Cancer Cell"},{"issue":"22","key":"1794_CR239","doi-asserted-by":"publisher","first-page":"10174","DOI":"10.1158\/0008-5472.Can-05-2639","volume":"65","author":"HK Reddy","year":"2005","unstructured":"Reddy HK, Mettus RV, Rane SG, Gra\u00f1a X, Litvin J, Reddy EP. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res. 2005;65(22):10174\u20138. https:\/\/doi.org\/10.1158\/0008-5472.Can-05-2639.","journal-title":"Cancer Res"},{"issue":"1","key":"1794_CR240","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2005.12.019","volume":"9","author":"MW Landis","year":"2006","unstructured":"Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell. 2006;9(1):13\u201322. https:\/\/doi.org\/10.1016\/j.ccr.2005.12.019.","journal-title":"Cancer Cell"},{"issue":"6841","key":"1794_CR241","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/35082500","volume":"411","author":"Q Yu","year":"2001","unstructured":"Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411(6841):1017\u201321. https:\/\/doi.org\/10.1038\/35082500.","journal-title":"Nature"},{"issue":"4","key":"1794_CR242","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","volume":"22","author":"YJ Choi","year":"2012","unstructured":"Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22(4):438\u201351. https:\/\/doi.org\/10.1016\/j.ccr.2012.09.015.","journal-title":"Cancer Cell"},{"issue":"1","key":"1794_CR243","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ccr.2010.05.025","volume":"18","author":"M Puyol","year":"2010","unstructured":"Puyol M, Mart\u00edn A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010;18(1):63\u201373. https:\/\/doi.org\/10.1016\/j.ccr.2010.05.025.","journal-title":"Cancer Cell"},{"issue":"4","key":"1794_CR244","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2004.08.002","volume":"118","author":"M Malumbres","year":"2004","unstructured":"Malumbres M, Sotillo Ro, Santamar\u0131\u0301a D, Gal\u00e1n J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell. 2004;118(4):493\u2013504.","journal-title":"Cell"},{"issue":"1","key":"1794_CR245","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/sj.bjc.6602229","volume":"92","author":"C Benson","year":"2005","unstructured":"Benson C, Kaye S, Workman P, Garrett M, Walton M, De Bono J. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer. 2005;92(1):7\u201312.","journal-title":"Br J Cancer"},{"issue":"4","key":"1794_CR246","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.Cd-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov. 2016;6(4):353\u201367. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-0894.","journal-title":"Cancer Discov"},{"issue":"11","key":"1794_CR247","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427\u201338.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1794_CR248","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/jm049354h","volume":"48","author":"PL Toogood","year":"2005","unstructured":"Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6. J Med Chem. 2005;48(7):2388\u2013406. https:\/\/doi.org\/10.1021\/jm049354h.","journal-title":"J Med Chem"},{"issue":"5","key":"1794_CR249","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.Ccr-14-2258","volume":"21","author":"A DeMichele","year":"2015","unstructured":"DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, et al. CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015;21(5):995\u20131001. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2258.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1794_CR250","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335. https:\/\/doi.org\/10.1016\/s1470-2045(14)71159-3.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1794_CR251","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719\u201329. https:\/\/doi.org\/10.1007\/s10549-018-05125-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1794_CR252","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1505270.","journal-title":"N Engl J Med"},{"issue":"4","key":"1794_CR253","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cancers17040561","volume":"17","author":"J Li","year":"2025","unstructured":"Li J. Exploring the Potential of Adjuvant CDK4\/6 Inhibitors in Hormone Receptor-Positive Early Breast Cancer: A Consistent Approach for All. Cancers. 2025;17(4):561.","journal-title":"Cancers"},{"key":"1794_CR254","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/dddt.S137783","volume":"12","author":"SP Corona","year":"2018","unstructured":"Corona SP, Generali D. Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HER2- advanced breast cancer. Drug Des Devel Ther. 2018;12:321\u201330. https:\/\/doi.org\/10.2147\/dddt.S137783.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"1794_CR255","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/1541-7786.Mcr-17-0468","volume":"16","author":"EM Cousins","year":"2018","unstructured":"Cousins EM, Goldfarb D, Yan F, Roques J, Darr D, Johnson GL, et al. Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3\u03b2 and Activates WNT Signaling. Mol Cancer Res. 2018;16(2):333\u201344. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-17-0468.","journal-title":"Mol Cancer Res"},{"key":"1794_CR256","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Rosen LS, Beeram M, Goldman JW, Gandhi L, Tolcher AW et al. Abstract P5-19-13: clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer. Cancer research. 2015;75(9_Supplement):P5-19-3-P5\u20133.","DOI":"10.1158\/1538-7445.SABCS14-P5-19-13"},{"key":"1794_CR257","doi-asserted-by":"crossref","unstructured":"Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. LY2835219, a novel cell cycle inhibitor selective for CDK4\/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. American Society of Clinical Oncology; 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.534"},{"key":"1794_CR258","doi-asserted-by":"publisher","first-page":"104148","DOI":"10.1016\/j.critrevonc.2023.104148","volume":"192","author":"G Antonarelli","year":"2023","unstructured":"Antonarelli G, Taurelli Salimbeni B, Marra A, Esposito A, Locatelli MA, Trapani D, et al. The CDK4\/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility. Crit Rev Oncol Hematol. 2023;192:104148. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104148.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"1794_CR259","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1124\/dmd.114.062745","volume":"43","author":"TJ Raub","year":"2015","unstructured":"Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, et al. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Drug Metab Dispos. 2015;43(9):1360\u201371. https:\/\/doi.org\/10.1124\/dmd.114.062745.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1794_CR260","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/cpt.2021","volume":"109","author":"J Li","year":"2021","unstructured":"Li J, Jiang J, Wu J, Bao X, Sanai N. Physiologically based pharmacokinetic modeling of central nervous system pharmacokinetics of CDK4\/6 inhibitors to guide selection of drug and dosing regimen for brain cancer treatment. Clin Pharmacol Ther. 2021;109(2):494\u2013506.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1794_CR261","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/1535-7163.Mct-15-0775","volume":"15","author":"JE Bisi","year":"2016","unstructured":"Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC. Preclinical Characterization of G1T28: A Novel CDK4\/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016;15(5):783\u201393. https:\/\/doi.org\/10.1158\/1535-7163.Mct-15-0775.","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"1794_CR262","doi-asserted-by":"publisher","first-page":"42343","DOI":"10.18632\/oncotarget.16216","volume":"8","author":"JE Bisi","year":"2017","unstructured":"Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, et al. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4\/6 for use as an oral antineoplastic in patients with CDK4\/6 sensitive tumors. Oncotarget. 2017;8(26):42343\u201358. https:\/\/doi.org\/10.18632\/oncotarget.16216.","journal-title":"Oncotarget"},{"issue":"7","key":"1794_CR263","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1172\/jci41402","volume":"120","author":"SM Johnson","year":"2010","unstructured":"Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4\/6 inhibition. J Clin Invest. 2010;120(7):2528\u201336. https:\/\/doi.org\/10.1172\/jci41402.","journal-title":"J Clin Invest"},{"issue":"37","key":"1794_CR264","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1038\/sj.onc.1206682","volume":"22","author":"G Iliakis","year":"2003","unstructured":"Iliakis G, Wang Y, Guan J, Wang H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene. 2003;22(37):5834\u201347. https:\/\/doi.org\/10.1038\/sj.onc.1206682.","journal-title":"Oncogene"},{"key":"1794_CR265","doi-asserted-by":"publisher","unstructured":"He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, et al. Transient CDK4\/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 2017;9(387). https:\/\/doi.org\/10.1126\/scitranslmed.aal3986.","DOI":"10.1126\/scitranslmed.aal3986"},{"issue":"7","key":"1794_CR266","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S, Trilaciclib. First Approval Drugs. 2021;81(7):867\u201374. https:\/\/doi.org\/10.1007\/s40265-021-01508-y.","journal-title":"First Approval Drugs"},{"issue":"4","key":"1794_CR267","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/cas.13957","volume":"110","author":"F Long","year":"2019","unstructured":"Long F, He Y, Fu H, Li Y, Bao X, Wang Q, et al. Preclinical characterization of SHR6390, a novel CDK 4\/6 inhibitor, in vitro and in human tumor xenograft models. Cancer Sci. 2019;110(4):1420\u201330.","journal-title":"Cancer Sci"},{"key":"1794_CR268","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-017-1231-7","volume":"15","author":"J Wang","year":"2017","unstructured":"Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z, et al. CDK4\/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J Translational Med. 2017;15:1\u201311.","journal-title":"J Translational Med"},{"issue":"11","key":"1794_CR269","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"B Xu","year":"2021","unstructured":"Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021;27(11):1904\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"1794_CR270","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/1535-7163.MCT-13-0858","volume":"13","author":"K Keegan","year":"2014","unstructured":"Keegan K, Li C, Li Z, Ma J, Ragains M, Coberly S, et al. Preclinical evaluation of AMG 925, a FLT3\/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. Mol Cancer Ther. 2014;13(4):880\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1794_CR271","doi-asserted-by":"publisher","unstructured":"Gao S, Liu R-J, Chen Y, Wang Y-q, Chen H, Zhang H-j, et al. A novel potent CDK4\/6 inhibitor BPI-16350 in preclinical cancer models. 2022. https:\/\/doi.org\/10.21203\/rs.3.rs-1333630\/v1.","DOI":"10.21203\/rs.3.rs-1333630\/v1"},{"key":"1794_CR272","doi-asserted-by":"crossref","unstructured":"Bozhenko VK, Kulinich TM, Kudinova EA, Boldyrev A, Solodkij VA. New targeted anti CDK4\/6 peptide MM-D37K. American Society of Clinical Oncology; 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.e13545"},{"key":"1794_CR273","doi-asserted-by":"publisher","first-page":"118340","DOI":"10.1016\/j.biopha.2025.118340","volume":"189","author":"LB Mekonnen","year":"2025","unstructured":"Mekonnen LB, Teo T, Noll B, Rahaman MH, Lenjisa J, Basnet S, et al. A brain-penetrant CDK4\/6 inhibitor-AU3-14 shows robust anti-tumor efficacy against glioblastoma. Biomed Pharmacother. 2025;189:118340.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1794_CR274","doi-asserted-by":"publisher","first-page":"106035","DOI":"10.1016\/j.esmoop.2025.106035","volume":"11","author":"T Teo","year":"2026","unstructured":"Teo T, Karanjia J, Wabnitz P, Kichenadasse G, Gan H, Cooper A, et al. A phase I\/IIa study of auceliciclib in patients with advanced solid tumours and in combination with temozolomide in patients with recurrent\/relapsed high-grade glioma. ESMO open. 2026;11(2):106035.","journal-title":"ESMO open"},{"issue":"6","key":"1794_CR275","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1158\/1541-7786.Mcr-17-0028","volume":"15","author":"JP Stice","year":"2017","unstructured":"Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, et al. CDK4\/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. Mol Cancer Res. 2017;15(6):660\u20139. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-17-0028.","journal-title":"Mol Cancer Res"},{"key":"1794_CR276","doi-asserted-by":"crossref","unstructured":"Profit\u00f3s-Pelej\u00e0 N, Ribeiro M, Parra J, Fern\u00e1ndez\u2010Serrano M, Mar\u00edn\u2010Escudero P, Makovski\u2010Silverstein A et al. Prolonged cell cycle arrest by the CDK4\/6 antagonist narazaciclib restores ibrutinib response in preclinical models of BTKi\u2010resistant mantle cell lymphoma. Hematol Oncol. 2023;41:553\u20134.","DOI":"10.1002\/hon.3164_414"},{"issue":"1","key":"1794_CR277","doi-asserted-by":"publisher","first-page":"9032","DOI":"10.1038\/s41598-024-59650-y","volume":"14","author":"T Yang","year":"2024","unstructured":"Yang T, Ke H, Liu J, An X, Xue J, Ning J, et al. Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models. Sci Rep. 2024;14(1):9032. https:\/\/doi.org\/10.1038\/s41598-024-59650-y.","journal-title":"Sci Rep"},{"issue":"1","key":"1794_CR278","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-19-0253","volume":"19","author":"SF Schoninger","year":"2020","unstructured":"Schoninger SF, Blain SW. The ongoing search for biomarkers of CDK4\/6 inhibitor responsiveness in breast cancer. Mol Cancer Ther. 2020;19(1):3\u201312.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1794_CR279","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/2159-8290.Cd-16-0095","volume":"6","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. 2016;6(7):740\u201353. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0095.","journal-title":"Cancer Discov"},{"issue":"11","key":"1794_CR280","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","volume":"42","author":"R Kudo","year":"2024","unstructured":"Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, et al. Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell. 2024;42(11):1919\u201335. e9.","journal-title":"Cancer Cell"},{"issue":"18","key":"1794_CR281","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.Ccr-17-0369","volume":"23","author":"US Asghar","year":"2017","unstructured":"Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, et al. Single-Cell Dynamics Determines Response to CDK4\/6 Inhibition in Triple-Negative Breast Cancer. Clin Cancer Res. 2017;23(18):5561\u201372. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-0369.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1794_CR282","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M. Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther. 2024;31(9):1283\u201391. https:\/\/doi.org\/10.1038\/s41417-024-00747-x.","journal-title":"Cancer Gene Ther"},{"issue":"Suppl 1","key":"1794_CR283","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1093\/oncolo\/oyac010","volume":"27","author":"A Jacobson","year":"2022","unstructured":"Jacobson A. Ribociclib Improves Overall Survival in HR+\/HER2- Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes. Oncologist. 2022;27(Suppl 1):S11\u20132. https:\/\/doi.org\/10.1093\/oncolo\/oyac010.","journal-title":"Oncologist"},{"issue":"2","key":"1794_CR284","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC. The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21(2):89\u2013105. https:\/\/doi.org\/10.1038\/s41571-023-00840-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"1794_CR285","doi-asserted-by":"publisher","unstructured":"Nabieva N, Fasching PA. CDK4\/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. Cancers (Basel). 2023;15(6). https:\/\/doi.org\/10.3390\/cancers15061763.","DOI":"10.3390\/cancers15061763"},{"issue":"1","key":"1794_CR286","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s1470-2045(19)30786-7","volume":"21","author":"A Prat","year":"2020","unstructured":"Prat A, Saura C, Pascual T, Hernando C, Mu\u00f1oz M, Par\u00e9 L, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33\u201343. https:\/\/doi.org\/10.1016\/s1470-2045(19)30786-7.","journal-title":"Lancet Oncol"},{"key":"1794_CR287","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejca.2022.01.014","volume":"166","author":"S Delaloge","year":"2022","unstructured":"Delaloge S, Dureau S, D\u2019Hondt V, Desmoulins I, Heudel PE, Duhoux FP, et al. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. Eur J Cancer. 2022;166:300\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.014.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1794_CR288","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1200\/jco.18.01624","volume":"37","author":"S Johnston","year":"2019","unstructured":"Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C, et al. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. J Clin Oncol. 2019;37(3):178\u201389. https:\/\/doi.org\/10.1200\/jco.18.01624.","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"1794_CR289","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14737140.2024.2330601","volume":"24","author":"A Stravodimou","year":"2024","unstructured":"Stravodimou A, Voutsadakis IA. Neo-adjuvant therapies for ER positive\/HER2 negative breast cancers: From chemotherapy to hormonal therapy, CDK inhibitors, and beyond. Expert Rev Anticancer Ther. 2024;24(3\u20134):117\u201335.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"1794_CR290","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-23-1209","volume":"30","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, Goel S, Nadal J, Denys H, Borrego MR, Litchfield LM, et al. Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus chemotherapy in HR+, HER2\u2009+\u2009metastatic breast cancer patients. Clin Cancer Res. 2024;30(1):39\u201349.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1794_CR291","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s43018-021-00198-5","volume":"2","author":"PK Brastianos","year":"2021","unstructured":"Brastianos PK, Kim AE, Wang N, Lee EQ, Ligibel J, Cohen JV, et al. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nat Cancer. 2021;2(5):498\u2013502.","journal-title":"Nat Cancer"},{"issue":"1","key":"1794_CR292","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41523-024-00646-2","volume":"10","author":"D Chen","year":"2024","unstructured":"Chen D, Xu F, Lu Y, Xia W, Du C, Xiong D, et al. Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+\/HER2\u2009+\u2009breast cancer patients with brain metastasis. NPJ Breast Cancer. 2024;10(1):45. https:\/\/doi.org\/10.1038\/s41523-024-00646-2.","journal-title":"NPJ Breast Cancer"},{"issue":"20","key":"1794_CR293","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","volume":"26","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor\u2013positive breast cancer. Clin Cancer Res. 2020;26(20):5310\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1794_CR294","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","volume":"26","author":"SR Vora","year":"2014","unstructured":"Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, et al. CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014;26(1):136\u201349. https:\/\/doi.org\/10.1016\/j.ccr.2014.05.020.","journal-title":"Cancer Cell"},{"key":"1794_CR295","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/bs.acr.2020.02.002","volume":"148","author":"X Gao","year":"2020","unstructured":"Gao X, Leone GW, Wang H. Cyclin D-CDK4\/6 functions in cancer. Adv Cancer Res. 2020;148:147\u201369. https:\/\/doi.org\/10.1016\/bs.acr.2020.02.002.","journal-title":"Adv Cancer Res"},{"issue":"11","key":"1794_CR296","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, et al. The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22(11):2978\u201394.","journal-title":"Cell Rep"},{"issue":"4","key":"1794_CR297","doi-asserted-by":"publisher","first-page":"188912","DOI":"10.1016\/j.bbcan.2023.188912","volume":"1878","author":"S Zhang","year":"2023","unstructured":"Zhang S, Xu Q, Sun W, Zhou J, Zhou J. Immunomodulatory effects of CDK4\/6 inhibitors. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2023;1878(4):188912.","journal-title":"Biochim et Biophys Acta (BBA)-Reviews Cancer"},{"issue":"5","key":"1794_CR298","doi-asserted-by":"publisher","first-page":"103525","DOI":"10.1016\/j.drudis.2023.103525","volume":"28","author":"A Safaroghli-Azar","year":"2023","unstructured":"Safaroghli-Azar A, Emadi F, Lenjisa J, Mekonnen L, Wang S. Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies. Drug Discov Today. 2023;28(5):103525. https:\/\/doi.org\/10.1016\/j.drudis.2023.103525.","journal-title":"Drug Discov Today"},{"key":"1794_CR299","doi-asserted-by":"publisher","unstructured":"Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, et al. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). J Immunother Cancer. 2023;11(9). https:\/\/doi.org\/10.1136\/jitc-2023-007126.","DOI":"10.1136\/jitc-2023-007126"},{"issue":"1","key":"1794_CR300","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41698-022-00273-9","volume":"6","author":"EJ Lelliott","year":"2022","unstructured":"Lelliott EJ, Sheppard KE, McArthur GA. Harnessing the immunotherapeutic potential of CDK4\/6 inhibitors in melanoma: is timing everything? NPJ Precis Oncol. 2022;6(1):26. https:\/\/doi.org\/10.1038\/s41698-022-00273-9.","journal-title":"NPJ Precis Oncol"},{"key":"1794_CR301","doi-asserted-by":"publisher","unstructured":"Garrido-Castro AC, Graham N, Ali LR, Herold C, Desrosiers J, Do K, et al. Phase I study of ribociclib (CDK4\/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer. J Immunother Cancer. 2025;13(2). https:\/\/doi.org\/10.1136\/jitc-2024-010430.","DOI":"10.1136\/jitc-2024-010430"},{"key":"1794_CR302","doi-asserted-by":"publisher","first-page":"891580","DOI":"10.3389\/fonc.2022.891580","volume":"12","author":"GL Rampioni Vinciguerra","year":"2022","unstructured":"Rampioni Vinciguerra GL, Sonego M, Segatto I, Dall\u2019Acqua A, Vecchione A, Baldassarre G, et al. CDK4\/6 inhibitors in combination therapies: better in company than alone: a mini review. Front Oncol. 2022;12:891580.","journal-title":"Front Oncol"},{"issue":"8","key":"1794_CR303","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-18-1161","volume":"19","author":"PJ Roberts","year":"2020","unstructured":"Roberts PJ, Kumarasamy V, Witkiewicz AK, Knudsen ES. Chemotherapy and CDK4\/6 inhibitors: unexpected bedfellows. Mol Cancer Ther. 2020;19(8):1575\u201388.","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"1794_CR304","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1158\/1078-0432.CCR-17-3575","volume":"24","author":"S Naz","year":"2018","unstructured":"Naz S, Sowers A, Choudhuri R, Wissler M, Gamson J, Mathias A, et al. Abemaciclib, a selective CDK4\/6 inhibitor, enhances the radiosensitivity of non\u2013small cell lung cancer in vitro and in vivo. Clin Cancer Res. 2018;24(16):3994\u20134005.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1794_CR305","doi-asserted-by":"publisher","first-page":"e1470","DOI":"10.1002\/cnr2.1470","volume":"5","author":"ESM van Aken","year":"2022","unstructured":"van Aken ESM, Beeker A, Houtenbos I, Pos FJ, Linn SC, Elkhuizen PHM, et al. Unexpected toxicity of CDK4\/6 inhibitor palbociclib and radiotherapy. Cancer Rep (Hoboken). 2022;5(2):e1470. https:\/\/doi.org\/10.1002\/cnr2.1470.","journal-title":"Cancer Rep (Hoboken)"},{"key":"1794_CR306","first-page":"100054","volume":"3","author":"A Dasgupta","year":"2021","unstructured":"Dasgupta A, Patafio F, Soliman H, Sahgal A, Trudeau M, Czarnota GJ. Radiation recall dermatitis with abemaciclib developing a year after radiotherapy. Curr Probl Cancer: Case Rep. 2021;3:100054.","journal-title":"Curr Probl Cancer: Case Rep"},{"key":"1794_CR307","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.breast.2019.05.001","volume":"46","author":"E Ippolito","year":"2019","unstructured":"Ippolito E, Greco C, Silipigni S, Dell\u2019Aquila E, Petrianni GM, Tonini G, et al. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity. Breast. 2019;46:70\u20134.","journal-title":"Breast"},{"issue":"6","key":"1794_CR308","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41416-020-0957-9","volume":"123","author":"A Beddok","year":"2020","unstructured":"Beddok A, Xu HP, Henry AA, Porte B, Fourquet A, Cottu P, et al. Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature. Br J Cancer. 2020;123(6):905\u20138.","journal-title":"Br J Cancer"},{"issue":"3","key":"1794_CR309","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.adro.2019.03.011","volume":"4","author":"M Chowdhary","year":"2019","unstructured":"Chowdhary M, Sen N, Chowdhary A, Usha L, Cobleigh MA, Wang D, et al. Safety and efficacy of palbociclib and radiation therapy in patients with metastatic breast cancer: initial results of a novel combination. Adv radiation Oncol. 2019;4(3):453\u20137.","journal-title":"Adv radiation Oncol"},{"issue":"5","key":"1794_CR310","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3390\/jcm12052044","volume":"12","author":"M Kubeczko","year":"2023","unstructured":"Kubeczko M, Jarz\u0105b M, Krzywon A, Gr\u00e4upner D, Polakiewicz-Gilowska A, Gabry\u015b D. Efficacy of CDK 4\/6 inhibitors and radiotherapy in breast cancer patients with brain metastases. J Clin Med. 2023;12(5):2044.","journal-title":"J Clin Med"},{"key":"1794_CR311","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ctro.2020.11.010","volume":"26","author":"C Bosacki","year":"2021","unstructured":"Bosacki C, Bouleftour W, Sotton S, Vallard A, Daguenet E, Ouaz H, et al. CDK 4\/6 inhibitors combined with radiotherapy: A review of literature. Clin Transl Radiat Oncol. 2021;26:79\u201385. https:\/\/doi.org\/10.1016\/j.ctro.2020.11.010.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"1794_CR312","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1055\/a-2286-6066","volume":"84","author":"A Schneeweiss","year":"2024","unstructured":"Schneeweiss A, Brucker SY, Huebner H, Volmer LL, Hack CC, Seitz K, et al. CDK4\/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current Programs. Geburtshilfe Frauenheilkd. 2024;84(5):443\u201358. https:\/\/doi.org\/10.1055\/a-2286-6066.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"1794_CR313","doi-asserted-by":"publisher","first-page":"103875","DOI":"10.1016\/j.breast.2025.103875","volume":"79","author":"P Zagami","year":"2025","unstructured":"Zagami P, Esposito A, Salimbeni BT, Giachetti PPMB, Scafetta R, Lambertini M, et al. Advancing treatment choices: CDK4\/6 inhibitor switching in HR+\/HER2-metastatic breast cancer. Breast. 2025;79:103875.","journal-title":"Breast"},{"issue":"12","key":"1794_CR314","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"key":"1794_CR315","doi-asserted-by":"publisher","first-page":"693104","DOI":"10.3389\/fonc.2021.693104","volume":"11","author":"MA George","year":"2021","unstructured":"George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S. Clinical and Pharmacologic Differences of CDK4\/6 Inhibitors in Breast Cancer. Front Oncol. 2021;11:693104. https:\/\/doi.org\/10.3389\/fonc.2021.693104.","journal-title":"Front Oncol"},{"issue":"10","key":"1794_CR316","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.3324\/haematol.2020.256313","volume":"106","author":"B Maurer","year":"2021","unstructured":"Maurer B, Brandstoetter T, Kollmann S, Sexl V, Prchal-Murphy M. Inducible deletion of CDK4 and CDK6 - deciphering CDK4\/6 inhibitor effects in the hematopoietic system. Haematologica. 2021;106(10):2624\u201332. https:\/\/doi.org\/10.3324\/haematol.2020.256313.","journal-title":"Haematologica"},{"issue":"9","key":"1794_CR317","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","volume":"22","author":"LM Spring","year":"2017","unstructured":"Spring LM, Zangardi ML, Moy B, Bardia A. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist. 2017;22(9):1039\u201348.","journal-title":"Oncologist"},{"issue":"3","key":"1794_CR318","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","volume":"21","author":"CE Onesti","year":"2021","unstructured":"Onesti CE, Jerusalem G. CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticancer Ther. 2021;21(3):283\u201398. https:\/\/doi.org\/10.1080\/14737140.2021.1852934.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"1794_CR319","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.Mct-18-0734","volume":"18","author":"S Thibault","year":"2019","unstructured":"Thibault S, Hu W, Hirakawa B, Kalabat D, Franks T, Sung T, et al. Intestinal Toxicity in Rats Following Administration of CDK4\/6 Inhibitors Is Independent of Primary Pharmacology. Mol Cancer Ther. 2019;18(2):257\u201366. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-0734.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"1794_CR320","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/cncr.34367","volume":"128","author":"NW Watson","year":"2022","unstructured":"Watson NW, Wander SA, Shatzel JJ, Al-Samkari H. Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer. Cancer. 2022;128(17):3224\u201332. https:\/\/doi.org\/10.1002\/cncr.34367.","journal-title":"Cancer"},{"issue":"6","key":"1794_CR321","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40259-019-00382-1","volume":"33","author":"M Santoni","year":"2019","unstructured":"Santoni M, Occhipinti G, Romagnoli E, Miccini F, Scoccia L, Giulietti M, et al. Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. BioDrugs. 2019;33(6):613\u201320. https:\/\/doi.org\/10.1007\/s40259-019-00382-1.","journal-title":"BioDrugs"},{"key":"1794_CR322","doi-asserted-by":"publisher","first-page":"1256783","DOI":"10.3389\/fonc.2023.1256783","volume":"13","author":"S Schaeffer","year":"2023","unstructured":"Schaeffer S, Lutz C, Dobbie M, Terracciano LM, Matter M, Vosbeck J, et al. Ribociclib-induced liver injury: a case report. Front Oncol. 2023;13:1256783. https:\/\/doi.org\/10.3389\/fonc.2023.1256783.","journal-title":"Front Oncol"},{"key":"1794_CR323","doi-asserted-by":"publisher","first-page":"1378090","DOI":"10.3389\/fphar.2024.1378090","volume":"15","author":"Y She","year":"2024","unstructured":"She Y, Guo Z, Zhai Q, Liu J, Du Q, Zhang Z. CDK4\/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network. Front Pharmacol. 2024;15:1378090. https:\/\/doi.org\/10.3389\/fphar.2024.1378090.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1794_CR324","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1158\/1541-7786.MCR-17-0172","volume":"15","author":"AI Sacaan","year":"2017","unstructured":"Sacaan AI, Thibault S, Hong M, Kondegowda NG, Nichols T, Li R, et al. CDK4\/6 inhibition on glucose and pancreatic beta cell homeostasis in young and aged rats. Mol Cancer Res. 2017;15(11):1531\u201341.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1794_CR325","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/8751","volume":"22","author":"SG Rane","year":"1999","unstructured":"Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet. 1999;22(1):44\u201352. https:\/\/doi.org\/10.1038\/8751.","journal-title":"Nat Genet"},{"key":"1794_CR326","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3389\/fonc.2019.00666","volume":"9","author":"A McCartney","year":"2019","unstructured":"McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F, et al. Mechanisms of Resistance to CDK4\/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Front Oncol. 2019;9:666. https:\/\/doi.org\/10.3389\/fonc.2019.00666.","journal-title":"Front Oncol"},{"issue":"5","key":"1794_CR327","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/1078-0432.Ccr-21-2947","volume":"28","author":"MR Lloyd","year":"2022","unstructured":"Lloyd MR, Spring LM, Bardia A, Wander SA. Mechanisms of Resistance to CDK4\/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2022;28(5):821\u201330. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-2947.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"1794_CR328","doi-asserted-by":"publisher","first-page":"eabb2210","DOI":"10.1126\/sciadv.abb2210","volume":"6","author":"A Fassl","year":"2020","unstructured":"Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, et al. Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4\/6 inhibition. Sci Adv. 2020;6(25):eabb2210. https:\/\/doi.org\/10.1126\/sciadv.abb2210.","journal-title":"Sci Adv"},{"issue":"20","key":"1794_CR329","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1038\/s41388-019-0695-8","volume":"38","author":"S Llanos","year":"2019","unstructured":"Llanos S, Megias D, Blanco-Aparicio C, Hern\u00e1ndez-Encinas E, Rovira M, Pietrocola F, et al. Lysosomal trapping of palbociclib and its functional implications. Oncogene. 2019;38(20):3886\u2013902. https:\/\/doi.org\/10.1038\/s41388-019-0695-8.","journal-title":"Oncogene"},{"issue":"6","key":"1794_CR330","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/0008-5472.Can-20-2828","volume":"81","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Jin X, Ma J, Ding D, Huang Z, Sheng H, et al. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4\/6 Inhibitor Resistance in Cancer. Cancer Res. 2021;81(6):1486\u201399. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-2828.","journal-title":"Cancer Res"},{"issue":"3","key":"1794_CR331","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1158\/1541-7786.Mcr-16-0319","volume":"15","author":"X Guan","year":"2017","unstructured":"Guan X, LaPak KM, Hennessey RC, Yu CY, Shakya R, Zhang J, et al. Stromal Senescence By Prolonged CDK4\/6 Inhibition Potentiates Tumor Growth. Mol Cancer Res. 2017;15(3):237\u201349. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-16-0319.","journal-title":"Mol Cancer Res"},{"issue":"11","key":"1794_CR332","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.Cd-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discov. 2018;8(11):1390\u2013403. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0264.","journal-title":"Cancer Discov"},{"issue":"3","key":"1794_CR333","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/annonc\/mdx784","volume":"29","author":"R Condorelli","year":"2018","unstructured":"Condorelli R, Spring L, O\u2019Shaughnessy J, Lacroix L, Bailleux C, Scott V, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2018;29(3):640\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdx784.","journal-title":"Ann Oncol"},{"issue":"8","key":"1794_CR334","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor\u2013positive metastatic breast cancer. Cancer Discov. 2020;10(8):1174\u201393.","journal-title":"Cancer Discov"},{"issue":"8","key":"1794_CR335","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.Can-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early Adaptation and Acquired Resistance to CDK4\/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res. 2016;76(8):2301\u201313. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-0728.","journal-title":"Cancer Res"},{"issue":"1","key":"1794_CR336","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s41467-025-56674-4","volume":"16","author":"V Kumarasamy","year":"2025","unstructured":"Kumarasamy V, Wang J, Roti M, Wan Y, Dommer AP, Rosenheck H, et al. Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nat Commun. 2025;16(1):1476.","journal-title":"Nat Commun"},{"issue":"15","key":"1794_CR337","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.Ccr-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, et al. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4\/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2017;23(15):4055\u201365. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3206.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1794_CR338","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","volume":"36","author":"C Yang","year":"2017","unstructured":"Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017;36(16):2255\u201364. https:\/\/doi.org\/10.1038\/onc.2016.379.","journal-title":"Oncogene"},{"issue":"47","key":"1794_CR339","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.18632\/oncotarget.27127","volume":"10","author":"M Iida","year":"2019","unstructured":"Iida M, Nakamura M, Tokuda E, Toyosawa D, Niwa T, Ohuchi N, et al. The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer. Oncotarget. 2019;10(47):4907\u201318. https:\/\/doi.org\/10.18632\/oncotarget.27127.","journal-title":"Oncotarget"},{"key":"1794_CR340","doi-asserted-by":"publisher","unstructured":"Scheidemann ER, Shajahan-Haq AN. Resistance to CDK4\/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Int J Mol Sci. 2021;22(22). https:\/\/doi.org\/10.3390\/ijms222212292.","DOI":"10.3390\/ijms222212292"},{"key":"1794_CR341","doi-asserted-by":"publisher","unstructured":"Lv S, Yang J, Lin J, Huang X, Zhao H, Zhao C, et al. CDK4\/6 inhibitors in lung cancer: current practice and future directions. Eur Respir Rev. 2024;33(171). https:\/\/doi.org\/10.1183\/16000617.0145-2023.","DOI":"10.1183\/16000617.0145-2023"},{"key":"1794_CR342","doi-asserted-by":"crossref","unstructured":"Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston SR, et al. Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy. American Society of Clinical Oncology; 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.3519"},{"issue":"1","key":"1794_CR343","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41467-024-45796-w","volume":"15","author":"J Ma","year":"2024","unstructured":"Ma J, Li L, Ma B, Liu T, Wang Z, Ye Q, et al. MYC induces CDK4\/6 inhibitors resistance by promoting pRB1 degradation. Nat Commun. 2024;15(1):1871.","journal-title":"Nat Commun"},{"issue":"1","key":"1794_CR344","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1373. https:\/\/doi.org\/10.1038\/s41467-019-09068-2.","journal-title":"Nat Commun"},{"issue":"60","key":"1794_CR345","doi-asserted-by":"publisher","first-page":"31572","DOI":"10.18632\/oncotarget.25803","volume":"9","author":"E Haines","year":"2018","unstructured":"Haines E, Chen T, Kommajosyula N, Chen Z, Herter-Sprie GS, Cornell L, et al. Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget. 2018;9(60):31572\u201389. https:\/\/doi.org\/10.18632\/oncotarget.25803.","journal-title":"Oncotarget"},{"key":"1794_CR346","doi-asserted-by":"publisher","unstructured":"Raimondi L, Raimondi FM, Pietranera M, Di Rocco A, Di Benedetto L, Miele E, et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4\/6 Inhibitors. Cancers (Basel). 2021;13(8). https:\/\/doi.org\/10.3390\/cancers13081928.","DOI":"10.3390\/cancers13081928"},{"issue":"17","key":"1794_CR347","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1158\/1078-0432.Ccr-18-0410","volume":"24","author":"R de Leeuw","year":"2018","unstructured":"de Leeuw R, McNair C, Schiewer MJ, Neupane NP, Brand LJ, Augello MA, et al. MAPK Reliance via Acquired CDK4\/6 Inhibitor Resistance in Cancer. Clin Cancer Res. 2018;24(17):4201\u201314. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0410.","journal-title":"Clin Cancer Res"},{"key":"1794_CR348","doi-asserted-by":"crossref","unstructured":"West MT, Goodyear S, Kaempf A, Kartika T, Ribkoff J, Hobbs E, et al. Molecular alterations associated with rapid progression following CDK4\/6 inhibitors (CDKi) in metastatic hormone receptor\u2013positive breast cancer (mHRBC). American Society of Clinical Oncology; 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.1054"},{"issue":"1","key":"1794_CR349","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","volume":"10","author":"C Costa","year":"2020","unstructured":"Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, et al. PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer. Cancer Discov. 2020;10(1):72\u201385.","journal-title":"Cancer Discov"},{"key":"1794_CR350","doi-asserted-by":"crossref","unstructured":"Lenihan C, Bouchekioua-Bouzaghou K, Shia A, Wilkes E, Casado-Izquierdo P 1, Cutillas P et al. Abstract P3-06-02: Characterization of resistance to the selective CDK4\/6 inhibitor palbociclib in ER positive breast cancer. Cancer Research. 2016;76(4_Supplement):P3-06-2-P3\u20132.","DOI":"10.1158\/1538-7445.SABCS15-P3-06-02"},{"issue":"9","key":"1794_CR351","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.Can-16-2653","volume":"77","author":"VM Jansen","year":"2017","unstructured":"Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, et al. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4\/6 Inhibition in ER-Positive Breast Cancer. Cancer Res. 2017;77(9):2488\u201399. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-2653.","journal-title":"Cancer Res"},{"issue":"6","key":"1794_CR352","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, et al. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4\/6 Inhibitors via the Hippo Pathway. Cancer Cell. 2018;34(6):893\u2013e9058. https:\/\/doi.org\/10.1016\/j.ccell.2018.11.006.","journal-title":"Cancer Cell"},{"issue":"15","key":"1794_CR353","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1002\/cncr.32931","volume":"126","author":"MN Sharifi","year":"2020","unstructured":"Sharifi MN, Anandan A, Grogan P, O\u2019Regan RM. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. Cancer. 2020;126(15):3400\u201316. https:\/\/doi.org\/10.1002\/cncr.32931.","journal-title":"Cancer"},{"key":"1794_CR354","doi-asserted-by":"crossref","unstructured":"Bonechi M, Migliaccio I, Benelli M, Romagnoli D, Bergqvist M, Mattsson K et al. Abstract P6-09-02: Effects of palbociclib on thymidine kinase-1 (TK1) in hormone receptor positive (HR+) breast cancer cell lines. Cancer Research. 2019;79(4_Supplement):P6-09-2-P6\u20132.","DOI":"10.1158\/1538-7445.SABCS18-P6-09-02"},{"issue":"1","key":"1794_CR355","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.Cd-18-0830","volume":"10","author":"C Costa","year":"2020","unstructured":"Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, et al. PTEN Loss Mediates Clinical Cross-Resistance to CDK4\/6 and PI3K\u03b1 Inhibitors in Breast Cancer. Cancer Discov. 2020;10(1):72\u201385. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0830.","journal-title":"Cancer Discov"},{"issue":"34","key":"1794_CR356","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1200\/jco.24.00427","volume":"42","author":"A Dilawari","year":"2024","unstructured":"Dilawari A, Buturla J, Osgood C, Gao X, Chen W, Ricks TK, et al. US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA\/AKT1\/PTEN Alterations. J Clin Oncol. 2024;42(34):4103\u201313. https:\/\/doi.org\/10.1200\/jco.24.00427.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1794_CR357","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim S-B, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392(12):1189\u2013202.","journal-title":"N Engl J Med"},{"issue":"4Supplement","key":"1794_CR358","first-page":"OT","volume":"81","author":"A Bardia","year":"2021","unstructured":"Bardia A, Barrios C, Dent R, Hu X, O\u2019Shaughnessy J, Yonemori K, et al. Abstract OT-03-09: trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator\u2019s choice of chemotherapy in patients with hormone receptor-positive (HR+), HER2 low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: a randomized, global phase 3 trial (DESTINY-Breast06). Cancer Res. 2021;81(4Supplement):OT. -03-9-OT\u20139.","journal-title":"Cancer Res"},{"key":"1794_CR359","doi-asserted-by":"crossref","unstructured":"Dent RA, Curigliano G, Hu X, Yonemori K, Barrios CH, Wildiers H, et al. Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in HER2-low\/ultralow, hormone receptor\u2013positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). American Society of Clinical Oncology; 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.1013"},{"key":"1794_CR360","doi-asserted-by":"publisher","unstructured":"Pandey K, Park N, Park KS, Hur J, Cho YB, Kang M, et al. Combined CDK2 and CDK4\/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence. Cancers (Basel). 2020;12(12). https:\/\/doi.org\/10.3390\/cancers12123566.","DOI":"10.3390\/cancers12123566"},{"issue":"1","key":"1794_CR361","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41698-022-00311-6","volume":"6","author":"AJ Al-Qasem","year":"2022","unstructured":"Al-Qasem AJ, Alves CL, Ehmsen S, Tuttolomondo M, Terp MG, Johansen LE, et al. Co-targeting CDK2 and CDK4\/6 overcomes resistance to aromatase and CDK4\/6 inhibitors in ER+ breast cancer. NPJ Precision Oncol. 2022;6(1):68.","journal-title":"NPJ Precision Oncol"},{"issue":"3","key":"1794_CR362","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.Cd-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich C, Trub A, Ahn A, Taylor M, Ambani K, Chan KT, et al. INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. Cancer Discov. 2024;14(3):446\u201367. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0954.","journal-title":"Cancer Discov"},{"issue":"13","key":"1794_CR363","doi-asserted-by":"publisher","first-page":"9056","DOI":"10.1021\/acs.jmedchem.1c00159","volume":"64","author":"KD Freeman-Cook","year":"2021","unstructured":"Freeman-Cook KD, Hoffman RL, Behenna DC, Boras B, Carelli J, Diehl W, et al. Discovery of PF-06873600, a CDK2\/4\/6 Inhibitor for the Treatment of Cancer. J Med Chem. 2021;64(13):9056\u201377. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00159.","journal-title":"J Med Chem"},{"key":"1794_CR364","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2147\/bctt.S434973","volume":"15","author":"W Hu","year":"2023","unstructured":"Hu W, Wang L, Luo J, Zhang J, Li N. The Potent Novel CDK4\/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models. Breast Cancer (Dove Med Press). 2023;15:899\u2013912. https:\/\/doi.org\/10.2147\/bctt.S434973.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"1794_CR365","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/1471-0528.18177","volume":"132","author":"T Zhou","year":"2025","unstructured":"Zhou T, Jiang Y, Che X, Jian F, Wang Y, Feng W. CDK4\/6 Inhibitor Can Improve Niraparib Sensitivity and Reverse Acquired Drug Resistance Through Endonuclease G Nuclear Translocation in BRCA Wild-Type Ovarian Cancer: A Vitro Study. BJOG: Int J Obstet Gynecol. 2025;132:20\u20138.","journal-title":"BJOG: Int J Obstet Gynecol"},{"issue":"1","key":"1794_CR366","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41392-025-02475-6","volume":"10","author":"Y Yin","year":"2025","unstructured":"Yin Y, Zhang Q, Sun T, Hao C, Wang Z, Yang J, et al. Novel CDK2\/4\/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. Signal Transduct Target Therapy. 2025;10(1):414.","journal-title":"Signal Transduct Target Therapy"},{"issue":"11","key":"1794_CR367","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1158\/1535-7163.MCT-06-0355","volume":"5","author":"W DePinto","year":"2006","unstructured":"DePinto W, Chu X-J, Yin X, Smith M, Packman K, Goelzer P, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther. 2006;5(11):2644\u201358.","journal-title":"Mol Cancer Ther"},{"key":"1794_CR368","doi-asserted-by":"publisher","unstructured":"Attia YM, Shouman SA, Salama SA, Ivan C, Elsayed AM, Amero P, et al. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer. Int J Mol Sci. 2020;21(8). https:\/\/doi.org\/10.3390\/ijms21082974.","DOI":"10.3390\/ijms21082974"},{"issue":"13","key":"1794_CR369","first-page":"149","volume":"19","author":"SA Wander","year":"2021","unstructured":"Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LS, et al. Clinical outcomes with abemaciclib after prior CDK4\/6 inhibitor progression in breast cancer: a multicenter experience. J Natl Compr Canc Netw. 2021;19(13):149\u201356.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1794_CR370","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11523-024-01036-1","volume":"19","author":"C Kang","year":"2024","unstructured":"Kang C. Sacituzumab govitecan: a review in unresectable or metastatic HR+\/HER2\u2009\u2013\u2009breast cancer. Target Oncol. 2024;19(2):289\u201396.","journal-title":"Target Oncol"},{"issue":"10411","key":"1794_CR371","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423\u201333.","journal-title":"Lancet"},{"key":"1794_CR372","doi-asserted-by":"crossref","unstructured":"Buonaiuto R, Fordellone M, Caltavituro A, Cataldo ML, Criscitiello C, Dieci MV, et al. Efficacy and safety of systemic therapies following progression on CDK4\/6 inhibitors in patients with HR+\/HER2\u2009\u2013\u2009metastatic breast cancer: a systematic review and network meta-analysis. EClinicalMedicine. 2025;89:103535.","DOI":"10.1016\/j.eclinm.2025.103535"},{"key":"1794_CR373","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2\u2013) metastatic breast cancer (mBC). American Society of Clinical Oncology; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.1003"},{"issue":"12","key":"1794_CR374","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","volume":"30","author":"B Xu","year":"2024","unstructured":"Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, et al. Sacituzumab govitecan in HR+ HER2\u2009\u2013\u2009metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024;30(12):3709\u201316.","journal-title":"Nat Med"},{"issue":"12","key":"1794_CR375","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/bjc.2011.177","volume":"104","author":"GK Schwartz","year":"2011","unstructured":"Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2\/1). Br J Cancer. 2011;104(12):1862\u20138. https:\/\/doi.org\/10.1038\/bjc.2011.177.","journal-title":"Br J Cancer"},{"issue":"2","key":"1794_CR376","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1078-0432.Ccr-11-0509","volume":"18","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568\u201376. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-0509.","journal-title":"Clin Cancer Res"},{"issue":"6Supplement","key":"1794_CR377","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1158\/1538-7445.AM2024-5701","volume":"84","author":"L Bantie","year":"2024","unstructured":"Bantie L, Likisa J, Rahaman M, Teo T, Safaroghliazar A, Basnet SK, et al. AU2-94: A CDK4-specific inhibitor with the marked anti-tumor efficacy. Cancer Res. 2024;84(6Supplement):5701.","journal-title":"Cancer Res"},{"key":"1794_CR378","doi-asserted-by":"crossref","unstructured":"Safaroghli-Azar A, Mekonnen LB, Hassankhani R, Lenjisa J, Basnet SK, Batayneh H, et al. A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. Investig New Drugs. 2025;43:728\u201341.","DOI":"10.1007\/s10637-025-01550-7"},{"key":"1794_CR379","doi-asserted-by":"crossref","unstructured":"Zhu H, Sun H, Xu W, Li J, Liu X, Zhang T, et al. Abstract P4-10-06: Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+ HER2-breast cancer models. Clinical Cancer Research. 2025;31(12_Supplement):P4-10-06-P4-10-06.","DOI":"10.1158\/1557-3265.SABCS24-P4-10-06"},{"issue":"8","key":"1794_CR380","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19(8):649\u201358. https:\/\/doi.org\/10.1016\/j.neo.2017.05.002.","journal-title":"Neoplasia"},{"issue":"11","key":"1794_CR381","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-21-2428","volume":"82","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Golomb L, Meyerson M. Functional genomic analysis of CDK4 and CDK6 gene dependency across human cancer cell lines. Cancer Res. 2022;82(11):2171\u201384.","journal-title":"Cancer Res"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01794-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:03:46Z","timestamp":1779210226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01794-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":381,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1794"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01794-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}